

CITATION REPORT

List of articles citing

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making

DOI: 10.1093/annonc/mds236
Annals of Oncology, 2012, 23, 2479-2516.

Source: <https://exaly.com/paper-pdf/53291535/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|------|---|------|-----------|
| 1122 | Clinical management of localized colon cancer with capecitabine. 2012 , 6, 363-73 | | 5 |
| 1121 | Has the new TNM classification for colorectal cancer improved care?. 2011 , 9, 119-23 | | 113 |
| 1120 | Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. 2013 , 13, 279 | | 203 |
| 1119 | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. 2013 , 13, 67 | | 37 |
| 1118 | Association of common gene variants in vitamin D modulating genes and colon cancer recurrence. 2013 , 139, 1457-64 | | 10 |
| 1117 | Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. 2013 , 9, 116-125 | | |
| 1116 | Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations. 2013 , 19, 619-29 | | 2 |
| 1115 | Evaluation of an endorectal electrode for performing focused irreversible electroporation ablations in the Swine rectum. 2013 , 24, 1249-56 | | 16 |
| 1114 | Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. 2013 , 36, 1664-1669 | | 13 |
| 1113 | Metachronous adenoma on ileorectal anastomosis suture line and submucosal deep invasive cancer suspected of rapid growth in rectal remnant following long-term interval after curative surgery for advanced colon cancer. 2013 , 25 Suppl 2, 46-51 | | 2 |
| 1112 | EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. 2013 , 49, 2784-90 | | 69 |
| 1111 | Optimum Duration of Metastatic Colorectal Cancer Treatment. 2013 , 9, 223-229 | | |
| 1110 | Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. 2013 , 17, 675-85 | | 25 |
| 1109 | Ultrasound elastography in patients with rectal cancer treated with chemoradiation. 2013 , 82, 913-7 | | 22 |
| 1108 | Rectal and Anal Cancer. 2013 , 167-184 | | |
| 1107 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi81-8 | 10.3 | 345 |
| 1106 | [Optimal timing of surgery for rectal cancer after neoadjuvant chemoradiotherapy: which patients would benefit from waiting?]. 2013 , 189, 904-6 | | 3 |

| | | |
|------|---|----------|
| 1105 | Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. 2013 , 13, 454 | |
| 1104 | Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. 2013 , 109, 1428-36 | 17 |
| 1103 | Biological markers: Tailoring treatment and trials to prognosis. 2013 , 10, 429-30 | 5 |
| 1102 | Epidermal growth factor receptor: pathway, therapies, and pipeline. 2013 , 35, 1282-303 | 66 |
| 1101 | Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. 2013 , 18, 872-9 | 17 |
| 1100 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. 2013 , 14, 1077-1085 | 438 |
| 1099 | Rectal cancer : when is the local recurrence risk low enough to refrain from the aim to prevent it?. 2013 , 189, 105-10 | 9 |
| 1098 | Neoadjuvant therapy before surgical treatment. 2013 , 11, 45-59 | 7 |
| 1097 | Evaluating national practice of preoperative radiotherapy for rectal cancer based on clinical auditing. 2013 , 39, 1000-6 | 26 |
| 1096 | Adjuvant chemotherapy. 2013 , 11, 72-9 | 1 |
| 1095 | The Optimal Staging of Rectal Cancer. 2013 , 9, 24-30 | |
| 1094 | Role of targeted agents in metastatic colorectal cancer. 2013 , 8, 83-96 | 52 |
| 1093 | Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. 2013 , 31, 1035-43 | 11 |
| 1092 | Cancer colorrectal. 2013 , 11, 1519-1525 | |
| 1091 | Improving outcomes in colorectal cancer: where do we go from here?. 2013 , 49, 2476-85 | 34 |
| 1090 | New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. 2013 , 73, 883-91 | 18 |
| 1089 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi64-72 | 10.3 580 |
| 1088 | Personalised cancer management: closer, but not here yet. <i>Annals of Oncology</i> , 2013 , 24, 1951-5 | 10.3 3 |

| | | |
|------|--|--------|
| 1087 | Japanese Society for Cancer of the Colon and Rectum Guidelines 2010 for the treatment of colorectal cancer: comparison with western guidelines. 2013 , 2, 179-190 | 6 |
| 1086 | Current Options for the Diagnosis, Staging and Therapeutic Management of Colorectal Cancer. 2013 , 1, 25-32 | 21 |
| 1085 | Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma. 2013 , 2013, 740195 | 27 |
| 1084 | Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer. 2013 , 2013, 610786 | 6 |
| 1083 | Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?. 2013 , 19, 6669-77 | 23 |
| 1082 | Outcomes of multimodality therapies for patients with stage II or III rectal cancer in California, 1994-2009. 2013 , 56, 1357-65 | 5 |
| 1081 | Long-term net survival in patients with colorectal cancer in France: an informative contribution of recent methodology. 2013 , 56, 1118-24 | 7 |
| 1080 | Systemic treatment of liver metastases from colorectal cancer. 2013 , 5, 193-203 | 6 |
| 1079 | Biomarkers in precision therapy in colorectal cancer. 2013 , 1, 166-83 | 69 |
| 1078 | Oxaliplatin for colorectal cancer: recent evidence from clinical trials. 2013 , 2, 135-144 | 1 |
| 1077 | Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy?. <i>Annals of Oncology</i> , 2013 , 24, 853 | 10.3 2 |
| 1076 | Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. 2013 , 2013, 143273 | 15 |
| 1075 | Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. 2013 , 119, 3570-7 | 69 |
| 1074 | Reply to K. Bujko and D. Tan et al. 2013 , 31, 1800-1 | |
| 1073 | Trial Watch: Anticancer radioimmunotherapy. 2013 , 2, e25595 | 75 |
| 1072 | A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. 2013 , 109, 395-400 | 157 |
| 1071 | Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. 2013 , 19, 2265-72 | 85 |
| 1070 | But some neoadjuvant schedules are more equal than others. 2013 , 31, 1799-800 | 8 |

| | | |
|------|---|----|
| 1069 | Managing colon cancer with good surgery and global guidelines. 2013 , 2, 103-104 | |
| 1068 | Locally advanced rectal cancer: new findings in anticancer therapy. 2013 , 2, 585-601 | |
| 1067 | Intermittent therapy in the palliative treatment of metastatic colorectal cancer. 2013 , 2, 219-232 | |
| 1066 | Optimaler Operationszeitpunkt nach neoadjuvanter Radiochemotherapie. 2013 , 16, 16-20 | |
| 1065 | Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). 2013 , 5, 377-85 | 10 |
| 1064 | Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. 2013 , 19, 8502-14 | 96 |
| 1063 | Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis. 2013 , 8, e80188 | 8 |
| 1062 | BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. 2013 , 8, e84604 | 40 |
| 1061 | Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. 2013 , 3, 313 | 31 |
| 1060 | Neo-adjuvant radiotherapy in rectal cancer. 2013 , 19, 8489-501 | 45 |
| 1059 | B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. 2014 , 9, e99008 | 60 |
| 1058 | Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. 2014 , 5, 262-71 | 83 |
| 1057 | Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. 2014 , 74, 1321-4 | 1 |
| 1056 | Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. 2014 , 35, 10237-48 | 32 |
| 1055 | Trial Watch: Radioimmunotherapy for oncological indications. 2014 , 3, e954929 | 36 |
| 1054 | Therapie von Lungenmetastasen kolorektaler Karzinome. 2014 , 9, 27-34 | |
| 1053 | Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 2014 , 48, 295-302 | 25 |
| 1052 | Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades. 2014 , 14, 816 | 22 |

| | | |
|------|---|---------|
| 1051 | EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. 2014 , 33, 77 | 9 |
| 1050 | A population-based cohort study on adherence to practice guidelines for adjuvant chemotherapy in colorectal cancer. 2014 , 14, 948 | 16 |
| 1049 | The role of adjuvant chemotherapy in stage II colorectal cancer patients. 2014 , 29, 1237-43 | 22 |
| 1048 | Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. 2014 , 16, 942-53 | 21 |
| 1047 | Efficacy of laparoscopic liver resection in colorectal liver metastases and the influence of preoperative chemotherapy. 2014 , 12, 351 | 15 |
| 1046 | Complete radiologic and metabolic response of colorectal liver metastasis after neoadjuvant chemotherapy: to resect or not?. 2014 , 5, 208-10 | |
| 1045 | First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. 2014 , 111, 241-8 | 28 |
| 1044 | Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. 2014 , 111, 1285-92 | 21 |
| 1043 | Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. 2014 , 110, 1008-13 | 56 |
| 1042 | The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. 2014 , 110, 435-40 | 216 |
| 1041 | Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature. 2014 , 7, 1455-1458 | 3 |
| 1040 | Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. <i>Annals of Oncology</i> , 2014 , 25, 1485-92 | 10.3 35 |
| 1039 | Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. 2014 , 13, 1777-1790 | 38 |
| 1038 | Tumor budding in upper gastrointestinal carcinomas. 2014 , 4, 216 | 31 |
| 1037 | The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. 2014 , 4, 29 | 35 |
| 1036 | Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. 2014 , 50, 2791-801 | 25 |
| 1035 | Differences in colon and rectal cancer chemosensitivity. 2014 , 3, 93-105 | 6 |
| 1034 | The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer. 2014 , 29, 1459-66 | 13 |

| | | |
|------|---|-----|
| 1033 | Laparoscopic surgery for rectal cancer: current status and future perspective. 2014 , 7, 2-10 | 22 |
| 1032 | Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. 2014 , 128, 879-91 | 46 |
| 1031 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. 2014 , 15, 1481-1492 | 114 |
| 1030 | Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1β in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. 2014 , 105, 1100-8 | 26 |
| 1029 | Preoperative treatment selection in rectal cancer: a population-based cohort study. 2014 , 40, 1782-8 | 16 |
| 1028 | Should a loop ileostomy closure in rectal cancer patients be done during or after adjuvant chemotherapy?. 2014 , 109, 266-9 | 17 |
| 1027 | Screening & staging of colorectal cancer. 2014 , 14, | 78 |
| 1026 | The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. 2014 , 12, 254 | 15 |
| 1025 | Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer. 2014 , 57, 1245-52 | 30 |
| 1024 | Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. 2014 , 38, 197-204 | 55 |
| 1023 | Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. 2014 , 4, 50 | 38 |
| 1022 | Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. 2014 , 110, 982-8 | 21 |
| 1021 | Colorectal Cancer. 2014 , 923-947 | |
| 1020 | Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. 2014 , 20, 4263-75 | 30 |
| 1019 | Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. 2014 , 10, 2643-57 | 4 |
| 1018 | Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer. 2014 , 39, e215-9 | 8 |
| 1017 | The magnetic resonance imaging-based approach for identification of high-risk patients with upper rectal cancer. 2014 , 260, 293-8 | 14 |
| 1016 | Acquired resistance to EGFR-targeted therapies in colorectal cancer. 2014 , 8, 1084-94 | 94 |

| | | |
|------|--|---------|
| 1015 | [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. 2014 , 85, 11-6 | 1 |
| 1014 | Peritoneal carcinomatosis in t4 colorectal cancer: occurrence and risk factors. 2014 , 21, 1686-91 | 31 |
| 1013 | MRI-based treatment of rectal cancer: is prognostication of the recurrence risk solid enough to render radiation redundant?. 2014 , 21, 197-204 | 8 |
| 1012 | Estudio de minimizaci3n de costes de panitumumab frente a cetuximab en combinaci3n con quimioterapia en primera l3nea y segunda l3nea en el c3ncer colorrectal metast3tico KRAS nativo en Espa3a. 2014 , 11, 135-145 | 1 |
| 1011 | Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001-2011. 2014 , 21, 2267-73 | 43 |
| 1010 | International quality assurance project in colorectal cancer-unifying diagnostic and histopathological evaluation. 2014 , 399, 473-9 | 6 |
| 1009 | Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy. 2014 , 21, 1853-61 | 10 |
| 1008 | CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. 2014 , 73, 409-16 | 18 |
| 1007 | [Chemotherapy of metastatic colorectal cancer]. 2014 , 55, 37-42 | 5 |
| 1006 | Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. 2014 , 15, 569-79 | 314 |
| 1005 | EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. <i>Annals of Oncology</i> , 2014 , 25, 858-863 | 10.3 64 |
| 1004 | The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma. 2014 , 69, 619-23 | 84 |
| 1003 | 'Toxgnostics': an unmet need in cancer medicine. 2014 , 14, 440-5 | 24 |
| 1002 | Prognostic stratification by extramural depth of tumor invasion of primary rectal cancer based on the Radiological Society of North America proposal. 2014 , 202, 1238-44 | 43 |
| 1001 | Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. 2014 , 31, 67-78 | 16 |
| 1000 | EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. 2014 , 50, 1.e1-1.e34 | 274 |
| 999 | New Targets and New Drug Development in Colorectal Cancer. 2014 , 10, 288-295 | 1 |
| 998 | Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes. 2014 , 40, 1171-81 | 16 |

| | | | |
|-----|---|------|-----|
| 997 | Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. 2014 , 106, djt322 | | 58 |
| 996 | A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. 2014 , 44, 383-7 | | 6 |
| 995 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii1-9 | 10.3 | 702 |
| 994 | Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2014 , 371, 1609-18 | | 663 |
| 993 | Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients. 2014 , 20, 2159-68 | | 29 |
| 992 | Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). <i>Annals of Oncology</i> , 2014 , 25, 1032-8 | 10.3 | 174 |
| 991 | Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. 2014 , 13, 145-55 | | 14 |
| 990 | How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. 2014 , 14, 743-8 | | 14 |
| 989 | Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. 2014 , 14, 510 | | 22 |
| 988 | Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. 2014 , 14, 521 | | 29 |
| 987 | A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. 2014 , 14, 605 | | 30 |
| 986 | Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. 2014 , 70, 719-25 | | 20 |
| 985 | Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. 2014 , 464, 655-62 | | 31 |
| 984 | Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?. 2014 , 140, 1489-94 | | 26 |
| 983 | Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. 2014 , 49, 1314-23 | | 63 |
| 982 | Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). 2014 , 14, 277 | | 12 |
| 981 | Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study. 2014 , 14, 385 | | 1 |
| 980 | Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. <i>Annals of Oncology</i> , 2014 , 25, 1356-1362 | 10.3 | 184 |

| | | |
|-----|--|----|
| 979 | Laparoscopic liver resection compared to open approach in patients with colorectal liver metastases improves further resectability: Oncological outcomes of a case-control matched-pairs analysis. 2014 , 40, 536-544 | 79 |
| 978 | Changes in colorectal cancer care in japan before and after guideline publication: a nationwide survey about D3 lymph node dissection and adjuvant chemotherapy. 2014 , 218, 969-977.e1 | 35 |
| 977 | Exploring better strategies for EGFR antibodies in colon cancer. 2014 , 15, 549-50 | 11 |
| 976 | Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. 2014 , 46, 561-7 | 11 |
| 975 | Adjuvant chemotherapy improves overall survival after TME surgery in mucinous carcinoma of the rectum. 2014 , 40, 240-5 | 10 |
| 974 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. 2014 , 40, 701-15 | 53 |
| 973 | Management of colorectal cancer presenting with synchronous liver metastases. 2014 , 11, 446-59 | 90 |
| 972 | Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. 2014 , 20, 3775-86 | 76 |
| 971 | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOX intensive regimen. 2014 , 44, 1820-30 | 10 |
| 970 | Multidisciplinary treatment of rectal cancer in 2014: where are we going?. 2014 , 20, 11249-61 | 16 |
| 969 | The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. 2014 , 4, e005012 | 13 |
| 968 | Challenges in determining the benefits of restaging after chemoradiotherapy for locally advanced rectal cancer. 2014 , 3, 121-125 | |
| 967 | Tumor budding in the clinical management of colon and rectal cancer. 2014 , 3, 387-403 | 4 |
| 966 | Rectal cancer with disseminated carcinomatosis of the bone marrow: report of a case. 2014 , 99, 518-22 | 7 |
| 965 | Toxgnostics: predicting and preventing chemotherapy-induced side effects. 2014 , 11, 683-685 | |
| 964 | PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. 2015 , 4, 371-82 | 20 |
| 963 | Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. 2015 , 20, 15-23 | 28 |
| 962 | Análisis de costo-efectividad de panitumumab + FOLFOX en CCRm RAS-WT. 2015 , 14, 250-258 | |

| | | |
|-----|---|-----|
| 961 | Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. 2015 , 7, 63 | 15 |
| 960 | Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. 2015 , 58, 556-65 | 24 |
| 959 | Multicenter Evaluation of Rectal cancer ReImaging POst Neoadjuvant (MERRION) Therapy. 2015 , 262, e53 | |
| 958 | Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center. 2015 , 4, 2058460115580877 | 2 |
| 957 | Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. 2015 , 15, 690 | 7 |
| 956 | Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. 2015 , 15, 764 | 24 |
| 955 | Biomarkers of Angiogenesis in Colorectal Cancer. 2015 , 7, 13-9 | 46 |
| 954 | Differentiation of high-risk stage I and II colon tumors based on evaluation of CAV1 gene expression. 2015 , 112, 408-14 | 6 |
| 953 | Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. 2015 , 58, 713-25 | 142 |
| 952 | Management of cancer of the colon and rectum. 224-241 | |
| 951 | Optimal delivery of colorectal cancer follow-up care: improving patient outcomes. 2015 , 6, 127-38 | 23 |
| 950 | Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. 2015 , 10, e0116527 | 25 |
| 949 | Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy. 2015 , 10, e0142190 | 55 |
| 948 | Treatment of metastatic colorectal cancer: focus on panitumumab. 2015 , 7, 189-98 | 11 |
| 947 | Clinicopathologic impacts of poorly differentiated cluster-based grading system in colorectal carcinoma. 2015 , 30, 16-23 | 22 |
| 946 | Treatment of colorectal cancer in the elderly. 2015 , 7, 204-20 | 58 |
| 945 | Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. 2015 , 112, 1874-81 | 25 |
| 944 | Supportive Care in Older Patients with Hematological Malignancies. 2015 , 277-296 | |

| | | |
|-----|---|-----|
| 943 | Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy. 2015 , 30, 753-60 | 10 |
| 942 | Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer. 2015 , 14, 192-7 | 1 |
| 941 | Integrating biomarkers in colorectal cancer trials in the West and China. 2015 , 12, 553-60 | 9 |
| 940 | Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. 2015 , 4, 1309-21 | 11 |
| 939 | Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases. 2015 , 13, 162 | 12 |
| 938 | . 2015 , | |
| 937 | Genetic or non-genetic prognostic factors in colon cancer. 2015 , | |
| 936 | Genetics, diagnosis and management of colorectal cancer (Review). 2015 , 34, 1087-96 | 189 |
| 935 | microRNAs and Colorectal Cancer. 2015 , 889, 89-103 | 12 |
| 934 | New hope on the horizon for patients with metastatic colorectal cancer. 2015 , 4, 229-239 | |
| 933 | Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. 2015 , 54, 5-16 | 182 |
| 932 | Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. 2015 , 10, 199-213 | 36 |
| 931 | Elderly patients with colorectal cancer are oncologically undertreated. 2015 , 41, 421-5 | 19 |
| 930 | Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. 2015 , 121, 527-34 | 83 |
| 929 | Incidence and patterns of late recurrences in rectal cancer patients. 2015 , 22, 520-7 | 15 |
| 928 | Critical evaluation of the scientific content in clinical practice guidelines. 2015 , 121, 1907-8 | 2 |
| 927 | Regorafenib: start low and go slow. 2015 , 10, 445-7 | 17 |
| 926 | Consequence of restaging after neoadjuvant treatment for locally advanced rectal cancer. 2015 , 22, 552-6 | 5 |

| | | | |
|-----|--|------|-----|
| 925 | Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015 , 26, 702-708 | 10.3 | 190 |
| 924 | Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. 2015 , 22, 916-23 | | 30 |
| 923 | Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. 2014 , 4, 5810 | | 30 |
| 922 | Glycosylation characteristics of colorectal cancer. 2015 , 126, 203-56 | | 95 |
| 921 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. 2015 , 141, 153-60 | | 24 |
| 920 | Hepatisch metastasiertes kolorektales Karzinom. 2015 , 21, 69-82 | | 0 |
| 919 | Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results. 2015 , 41, 478-83 | | 77 |
| 918 | Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. 2015 , 33, 740-50 | | 73 |
| 917 | Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. 2015 , 25, 2693-700 | | 20 |
| 916 | Prognostic value of HLA class I expression in patients with colorectal cancer. 2015 , 13, 36 | | 16 |
| 915 | Reply to ESMO guidelines committee comment on 'critical evaluation of the scientific content in clinical practice guidelines'. 2015 , 121, 1908-9 | | |
| 914 | Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. 2015 , 51, 18-26 | | 18 |
| 913 | Radiotherapy and Chemoradiation for Rectal Cancer: State of the Art in Europe, the USA and Asia. 2015 , 133-146 | | |
| 912 | Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). 2015 , 51, 1927-36 | | 113 |
| 911 | Is the benefit of oxaliplatin in rectal cancer clinically relevant?. 2015 , 16, 883-5 | | 6 |
| 910 | Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. 2015 , 91, 294-302 | | 7 |
| 909 | Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 2102-6 | 10.3 | 18 |
| 908 | Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. 2015 , 14, 99-105 | | 2 |

| | | |
|-----|--|-----|
| 907 | Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer. 2015 , 47, 259-65 | 11 |
| 906 | Alimentation et cancer colorectal. 2015 , 50, 262-270 | 2 |
| 905 | Prognostic value of poorly differentiated clusters in the primary tumor in patients undergoing hepatectomy for colorectal liver metastasis. 2015 , 157, 899-908 | 19 |
| 904 | Short-course radiotherapy with delayed surgery versus conventional chemoradiotherapy: A comparison of the short- and long-term outcomes in patients with T3 rectal cancer. 2015 , 158, 225-35 | 20 |
| 903 | Personalized treatment for patients with colorectal cancer: role of biomarkers. 2015 , 9, 337-47 | 18 |
| 902 | Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 2015 , 75, 993-1004 | 10 |
| 901 | Rate and patterns of ICU admission among colorectal cancer patients: a single-center experience. 2015 , 23, 1779-85 | 8 |
| 900 | First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. 2015 , 11, 54-69 | |
| 899 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. 2015 , 15, 125 | 23 |
| 898 | Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 2015 , 15, 235 | 34 |
| 897 | Staple-line recurrence arising 10 years after functional end-to-end anastomosis for colon cancer: a case report. 2015 , 1, 7 | 3 |
| 896 | Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. 2015 , 54, 1714-22 | 51 |
| 895 | Linking the future of anticancer metal-complexes to the therapy of tumour metastases. 2015 , 44, 8818-35 | 151 |
| 894 | A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. 2015 , 75, 587-94 | 6 |
| 893 | BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. 2015 , 112, 1921-8 | 111 |
| 892 | Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. 2015 , 36, 7897-906 | 26 |
| 891 | Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. 2015 , 58, 186-92 | 16 |
| 890 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. 2015 , 20, 207-39 | 467 |

| | | |
|-----|--|-----|
| 889 | Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. 2015 , 14, 170-6 | 18 |
| 888 | Pathologic evaluation of the response of mesorectal positive nodes to preoperative chemoradiotherapy in patients with rectal cancer. 2015 , 157, 743-51 | 14 |
| 887 | Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. 2015 , 51, 2553-61 | 62 |
| 886 | Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study. 2015 , 46, 343-9 | 4 |
| 885 | Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. 2015 , 15, 327 | 12 |
| 884 | Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer. 2015 , 15, 419 | 14 |
| 883 | [Lymph node dissection after primary surgery and neoadjuvant radiochemotherapy of rectal cancer. Interim analysis of a multicenter prospective observational study (OCUM)]. 2015 , 86, 1132-7 | 3 |
| 882 | A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. 2015 , 15, 601 | 12 |
| 881 | Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). 2015 , 15, 517 | 9 |
| 880 | Comparison of the pathological response of the mesorectal positive nodes between short-course chemoradiotherapy with delayed surgery and long-course chemoradiotherapy in patients with rectal cancer. 2015 , 30, 1339-47 | 5 |
| 879 | Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs. 2015 , 48, 228-35 | 4 |
| 878 | Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis. 2015 , 113, 763-72 | 30 |
| 877 | How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). 2015 , 11, 151-159 | 2 |
| 876 | Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. 2015 , 33, 3718-26 | 89 |
| 875 | Palliative treatment of colorectal cancer with secondary metastasis resection in Germany - impact of the multidisciplinary treatment approach on prognosis and cost: the Northern Bavaria IVOPAK I Project. 2015 , 88, 103-21 | 8 |
| 874 | Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. 2015 , 33, 3733-40 | 159 |
| 873 | The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. 2015 , 11, 1471-8 | 5 |
| 872 | Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. 2015 , 33, 209-17 | 219 |

| | | |
|-----|---|----------|
| 871 | Laparoscopic versus open resection for colorectal liver metastases: a single-center study with propensity score analysis. 2015 , 25, 12-20 | 40 |
| 870 | Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. 2015 , 29, 43-60 | 24 |
| 869 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. <i>Annals of Oncology</i> , 2015 , 26, 463-76 | 10.3 230 |
| 868 | Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. 2015 , 54, 179-86 | 18 |
| 867 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. 2015 , 22, 187-94 | 41 |
| 866 | Radiation-induced liver damage: correlation of histopathology with hepatobiliary magnetic resonance imaging, a feasibility study. 2015 , 38, 213-21 | 19 |
| 865 | BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. 2016 , 29, 173-179 | 6 |
| 864 | Anemia and iron deficiency in gastrointestinal and liver conditions. 2016 , 22, 7908-25 | 67 |
| 863 | Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. 2016 , 22, 1745-55 | 193 |
| 862 | New trends in molecular and cellular biomarker discovery for colorectal cancer. 2016 , 22, 5678-93 | 47 |
| 861 | A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. 2016 , 7, 19060-71 | 18 |
| 860 | Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. 2016 , 35, 92-102 | 6 |
| 859 | Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. 2016 , 12, 3127-3134 | 0 |
| 858 | Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. 2016 , 6, 21-30 | 7 |
| 857 | The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. 2016 , 17, | 24 |
| 856 | Tumor Budding: The Name is EMT. Partial EMT. 2016 , 5, | 258 |
| 855 | Chemopreventive and Therapeutic Effects of Edible Berries: A Focus on Colon Cancer Prevention and Treatment. 2016 , 21, 169 | 95 |
| 854 | hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. 2016 , 11, e0163711 | 7 |

| | | | |
|-----|--|------|------|
| 853 | Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly. 2016 , 25, 753-63 | | 3 |
| 852 | Gremlin1 expression associates with serrated pathway and favourable prognosis in colorectal cancer. 2016 , 69, 831-838 | | 12 |
| 851 | Effect of Neoadjuvant Radiation Dose and Schedule on Nodal Count and Its Prognostic Impact in Stage II-III Rectal Cancer. 2016 , 23, 3899-3906 | | 8 |
| 850 | Prognostic impact of the number of retrieved lymph nodes in patients with gastric cancer. 2016 , 31, 1566-71 | | 26 |
| 849 | Does Preoperative Neutrophil to Lymphocyte Ratio Predict Disease-Free Survival Rate in Colorectal Cancer Patients Undergoing Curative Surgery?. 2016 , 263, e80 | | |
| 848 | DrugTargetInspector: An assistance tool for patient treatment stratification. 2016 , 138, 1765-76 | | 8 |
| 847 | Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. 2016 , 139, 446-56 | | 107 |
| 846 | Treatment sequence of synchronously (liver) metastasized colon cancer. 2016 , 48, 1119-23 | | 12 |
| 845 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422 | 10.3 | 1683 |
| 844 | Reply to T. Magnes et al. 2016 , 34, 2434-5 | | 2 |
| 843 | Postoperative wound infections after a proctectomy--Patient experiences. 2016 , 11, 30393 | | 2 |
| 842 | Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. 2016 , 75, 965-73 | | 121 |
| 841 | Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example. 2016 , 1, e000021 | | 7 |
| 840 | Does shared decision making exist in oncologic practice?. 2016 , 55, 125-8 | | 4 |
| 839 | Improving definition of the term "synchronous liver metastases" from colorectal cancer. 2016 , 15, 458-460 | | 3 |
| 838 | Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. 2016 , 22, 3488-98 | | 20 |
| 837 | Impact of age on the prognostic value of number of lymph nodes retrieved in patients with stage II colorectal cancer. 2016 , 31, 1307-13 | | 4 |
| 836 | Non-surgical treatment of localized rectal cancer is an experimental option. 2016 , 94, 311-2 | | |

| | | |
|-----|---|----|
| 835 | Right colon cancer: Left behind. 2016 , 42, 1343-9 | 16 |
| 834 | Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. 2016 , 55, 881-5 | 6 |
| 833 | Association of perioperative blood pressure with long-term survival in rectal cancer patients. 2016 , 35, 38 | 6 |
| 832 | Watch-and-wait versus surgical resection for patients with rectal cancer. 2016 , 17, e133-e134 | 1 |
| 831 | Advanced imaging of colorectal cancer: From anatomy to molecular imaging. 2016 , 7, 285-309 | 14 |
| 830 | Diagnosis of lateral pelvic lymph node metastasis of T1 lower rectal cancer using diffusion-weighted magnetic resonance imaging: A case report with lateral pelvic lymph node dissection of lower rectal cancer. 2016 , 4, 817-820 | 3 |
| 829 | Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. 2016 , 47, 264-72 | 2 |
| 828 | Survival and Prognostic Factors of Colorectal Liver Metastases After Surgical and Nonsurgical Treatment. 2016 , 15, e183-e192 | 12 |
| 827 | A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. 2016 , 16, 91 | 22 |
| 826 | Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. 2016 , 15, 352-359.e1 | 9 |
| 825 | A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. 2016 , 67, 11-20 | 40 |
| 824 | Non-Surgical Treatment of Localized Rectal Cancer Is an Experimental Option. 2016 , 94, 311-312 | |
| 823 | Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy. 2016 , 5, e242 | 12 |
| 822 | Nomogram for predicting recurrence in stage II colorectal cancer. 2016 , 55, 1414-1417 | 24 |
| 821 | A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. 2016 , 212, 700-714 | 6 |
| 820 | A novel histologic grading scheme based on poorly differentiated clusters is applicable to treated rectal cancer and is associated with established histopathological prognosticators. 2016 , 5, 1510-8 | 13 |
| 819 | Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis. 2016 , 31, 1126-32 | 48 |
| 818 | Time to Initiation of Adjuvant Chemotherapy in Colon Cancer: Comparison of Open, Laparoscopic, and Robotic Surgery. 2016 , 26, 799-805 | 14 |

| | | |
|-----|---|-----|
| 817 | No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy. 2016 , 52, 539-547 | 11 |
| 816 | Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. 2016 , 29, 196-204 | 9 |
| 815 | What is most relevant in preoperative rectal cancer chemoradiotherapy - the chemotherapy, the radiation dose or the timing to surgery?. 2016 , 55, 1381-1385 | 7 |
| 814 | Interdisziplinäre Therapie kolorektaler Lebermetastasen. 2016 , 11, 479-488 | 2 |
| 813 | Survival among clinical stage I-III rectal cancer patients treated with different preoperative treatments: A population-based comparison. 2016 , 43, 35-41 | 2 |
| 812 | The impact of body mass index on oncological outcomes in colorectal cancer patients with curative intent. 2016 , 21, 1102-1110 | 4 |
| 811 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. 2016 , 51, 54-62 | 19 |
| 810 | Cancer and liver cirrhosis: implications on prognosis and management. 2016 , 1, e000042 | 124 |
| 809 | Nomograms to predict survival after colorectal cancer resection without preoperative therapy. 2016 , 16, 658 | 39 |
| 808 | miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. 2016 , 7, 12436 | 52 |
| 807 | Aktuelle Diagnostik und Therapie des Rektumkarzinoms. 2016 , 11, 489-494 | |
| 806 | Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. 2016 , 6, 36149 | 18 |
| 805 | The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. 2016 , 9, 861-886 | 37 |
| 804 | Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer. 2016 , 8, 1449-1452 | 5 |
| 803 | Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014. 2016 , 11, 58 | 3 |
| 802 | Minimally Invasive Colorectal Cancer Surgery in Europe: Implementation and Outcomes. 2016 , 95, e3812 | 14 |
| 801 | Heterotrimeric G protein signaling via GIV/Girdin: Breaking the rules of engagement, space, and time. 2016 , 38, 379-93 | 33 |
| 800 | Möglichkeiten der lokal-ablativen Bestrahlung (SBRT) bei metastasiertem kolorektalem Karzinom. 2016 , 22, 115-120 | 0 |

| | | |
|-----|---|-----|
| 799 | Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. 2016 , 15, 25 | 7 |
| 798 | Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. 2016 , 63, 110-7 | 20 |
| 797 | Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. 2016 , 9, 251-5 | 4 |
| 796 | Bone morphogenetic protein 7 is associated with the nodal invasion of colon cancer. 2016 , 11, 1707-1712 | 8 |
| 795 | Advances in adjuvant therapy of colon cancer. 2016 , 27, 204-212 | |
| 794 | Risk factors for survival and recurrence after lung metastasectomy. 2016 , 203, 293-300 | 13 |
| 793 | [Surgery for pulmonary metastases from colorectal cancer: Predictive factors for survival]. 2016 , 33, 838-852 | 10 |
| 792 | Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. 2016 , 63, 11-24 | 63 |
| 791 | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. 2016 , 7, 176-86 | 8 |
| 790 | Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. 2016 , 16, 110 | 7 |
| 789 | Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. 2016 , 8, 144-52 | 5 |
| 788 | Trends in colorectal cancer in the elderly in Denmark, 1980-2012. 2016 , 55 Suppl 1, 29-39 | 25 |
| 787 | Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. 2016 , 45, 97-104 | 4 |
| 786 | DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. 2016 , 22, 1621-31 | 11 |
| 785 | Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. 2016 , 22, 3037-47 | 41 |
| 784 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. 2016 , 11, 383-400 | 33 |
| 783 | Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation. 2016 , 27, 439-46 | 3 |
| 782 | Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort. 2016 , 23, 1352-60 | 126 |

| | | |
|-----|---|-----|
| 781 | High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). 2016 , 23, 2161-6 | 11 |
| 780 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). 2016 , 21, 705-712 | 4 |
| 779 | Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. 2016 , 54, 40-48 | 82 |
| 778 | Colorectal cancer with synchronous hepatic metastases: Systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. 2016 , 42, 159-65 | 40 |
| 777 | Rectal Cancer. 2016 , 992-1018.e6 | 4 |
| 776 | Intermediate Neoadjuvant Radiotherapy Combined With Total Mesorectal Excision for Locally Advanced Rectal Cancer: Outcomes After a Median Follow-Up of 5 Years. 2016 , 15, 152-7 | 5 |
| 775 | The feasibility of laparoscopic extended pelvic surgery for rectal cancer. 2016 , 46, 950-6 | 2 |
| 774 | Tumor budding in colorectal cancer--ready for diagnostic practice?. 2016 , 47, 4-19 | 134 |
| 773 | Practical problems of measuring depth of submucosal invasion in T1 colorectal carcinomas. 2016 , 31, 137-46 | 26 |
| 772 | Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. 2016 , 26, 674-82 | 70 |
| 771 | Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. 2017 , 66, 107-117 | 84 |
| 770 | 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). 2017 , 23, 396-398 | 4 |
| 769 | SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer. 2017 , 19, 135-148 | 1 |
| 768 | Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. 2017 , 19, 189-196 | 22 |
| 767 | Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. 2017 , 20, 574-584 | 6 |
| 766 | [Local ablative radiotherapy of oligometastatic colorectal cancer]. 2017 , 57, 105-110 | 4 |
| 765 | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. 2017 , 16, e153-e163 | 70 |
| 764 | Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. 2017 , 116, 464-471 | 19 |

| | | |
|-----|--|----|
| 763 | Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. 2017 , 402, 57-67 | 4 |
| 762 | Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. 2017 , 77, 1730-1740 | 16 |
| 761 | Second-line systemic therapy for metastatic colorectal cancer. 2017 , 1, CD006875 | 17 |
| 760 | Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. 2017 , 116, 1012-1020 | 29 |
| 759 | Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities. 2017 , 123, 2338-2351 | 4 |
| 758 | Oncologic relevance of magnetic resonance imaging-detected threatened mesorectal fascia for patients with mid or low rectal cancer: A longitudinal analysis before and after long-course, concurrent chemoradiotherapy. 2017 , 162, 152-163 | 6 |
| 757 | Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. 2017 , 17, 48 | 11 |
| 756 | Histopathologic risk stratification of stage IIB colorectal cancer. 2017 , 47, 934-939 | |
| 755 | Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?. 2017 , 19, 237-242 | 1 |
| 754 | Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival. 2017 , 19, 731-738 | 14 |
| 753 | On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. 2017 , 122, 1-10 | 21 |
| 752 | Mesenchymal Stem Cells Induce Epithelial to Mesenchymal Transition in Colon Cancer Cells through Direct Cell-to-Cell Contact. 2017 , 19, 429-438 | 44 |
| 751 | Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. 2017 , 14, 197-201 | 2 |
| 750 | Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer. 2017 , 17, 325 | 29 |
| 749 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. 2017 , 400, 183-193 | 37 |
| 748 | Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases. 2017 , 213, 1002-1009 | 5 |
| 747 | Need for adjuvant chemotherapy after colon cancer surgery - has it decreased?. 2017 , 56, 629-633 | 5 |
| 746 | Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. 2017 , 32, 149-160 | 61 |

| | | |
|-----|---|----|
| 745 | Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. 2017 , 123, 3513-3523 | 27 |
| 744 | A pilot randomized study comparing extralevator with conventional abdominoperineal excision for low rectal cancer after neoadjuvant chemoradiation. 2017 , 19, O253-O262 | 3 |
| 743 | Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. 2017 , 43, 1668-1681 | 34 |
| 742 | Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice. 2017 , 43, 1481-1487 | 4 |
| 741 | The association between microsatellite instability and lymph node count in colorectal cancer. 2017 , 471, 57-64 | 7 |
| 740 | Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. 2017 , 18, e354-e363 | 57 |
| 739 | Long-term outcomes in ypT0 rectal cancers: An international multi-centric investigation on behalf of Italian Society of Surgical Oncology Young Board (YSICO). 2017 , 43, 1472-1480 | 7 |
| 738 | Population-based study to re-evaluate optimal lymph node yield in colonic cancer. 2017 , 104, 1087-1096 | 13 |
| 737 | Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC). 2017 , 7, e015018 | 5 |
| 736 | Survival analysis of the CEAwatch multicentre clustered randomized trial. 2017 , 104, 1069-1077 | 15 |
| 735 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. 2018 , 249, 145-159 | 1 |
| 734 | Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. 2017 , 92, 135-141 | 4 |
| 733 | Comorbidity and the risk of anastomotic leak in Chinese patients with colorectal cancer undergoing colorectal surgery. 2017 , 32, 947-953 | 18 |
| 732 | Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer. 2017 , 16, 71 | 13 |
| 731 | A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines. 2017 , 47, 1086-1093 | 8 |
| 730 | Quality of Cancer Surveillance Clinical Practice Guidelines: Specificity and Consistency of Recommendations. 2017 , 177, 701-709 | 11 |
| 729 | Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer. 2017 , 21, 770-777 | 17 |
| 728 | Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. 2017 , 19, 224-236 | 56 |

| | | |
|-----|---|-----|
| 727 | Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer. 2017 , 71, 51-52 | |
| 726 | International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. 2017 , 117, 1427-1441 | 111 |
| 725 | Down-regulated long non-coding RNA SNHG1 inhibits tumor genesis of colorectal carcinoma. 2017 , 20, 67-73 | 27 |
| 724 | Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. 2017 , 80, 777-785 | 7 |
| 723 | Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis. 2017 , 14, 1491-1499 | 5 |
| 722 | Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. 2017 , 117, 1286-1294 | 17 |
| 721 | Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. 2017 , 118, 54-62 | 37 |
| 720 | Karyopherin β is a reliable marker for identification of patients with high-risk stage II colorectal cancer. 2017 , 143, 2493-2503 | 12 |
| 719 | Desmoplastic Pattern at the Tumor Front Defines Poor-prognosis Subtypes of Colorectal Cancer. 2017 , 41, 1506-1512 | 51 |
| 718 | Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancer. 2017 , 58, 559-566 | 3 |
| 717 | Bowel Dysfunction and Self-management for Bowel Symptoms After Sphincter-Preserving Surgery: A Cross-sectional Survey of Chinese Rectal Cancer Patients. 2017 , 40, E9-E16 | 5 |
| 716 | Prediction of lateral pelvic lymph node metastasis from lower rectal cancer using magnetic resonance imaging and risk factors for metastasis: Multicenter study of the Lymph Node Committee of the Japanese Society for Cancer of the Colon and Rectum. 2017 , 32, 1479-1487 | 13 |
| 715 | Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis. 2017 , 96, e6362 | 5 |
| 714 | Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. 2017 , 83, 302-312 | 12 |
| 713 | Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer. 2017 , 7, 17488 | 12 |
| 712 | MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma. 2017 , 34, 431-440 | 13 |
| 711 | Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma. 2017 , 15, 14 | 12 |
| 710 | Protein content and functional characteristics of serum-purified exosomes from patients with colorectal cancer revealed by quantitative proteomics. 2017 , 140, 900-913 | 79 |

| | | |
|-----|---|----|
| 709 | Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases. 2017 , 24, 236-243 | 8 |
| 708 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. 2017 , 24, 167-175 | 26 |
| 707 | The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer. 2017 , 8, 37-43 | 4 |
| 706 | The impact of the radiation-induced regression of positive nodes on survival in patients with rectal cancer treated with chemoradiotherapy. 2017 , 161, 422-432 | 4 |
| 705 | Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer. 2017 , 33, 393-401 | 21 |
| 704 | Decision-making in rectal and colorectal cancer: systematic review and qualitative analysis of surgeons' preferences. 2017 , 22, 434-448 | 4 |
| 703 | Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice. 2017 , 43, 364-371 | 9 |
| 702 | Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer. 2017 , 43, 92-99 | 17 |
| 701 | Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography for the detection of proximal synchronous lesions in patients with obstructive colorectal cancer. 2017 , 32, 401-408 | 5 |
| 700 | A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer. 2017 , 56, 634-638 | 12 |
| 699 | Accuracy of pre-treatment locoregional rectal cancer staging in a national improvement project. 2017 , 117, 104-109 | 3 |
| 698 | Lymph node retrieval after dissolution of surrounding adipose tissue for pathological examination of colorectal cancer. 2018 , 15, 2495-2500 | 2 |
| 697 | Advanced Diagnosis and New Findings Using MRI in the Treatment of Anorectal Diseases. 2017 , 70, 645-654 | |
| 696 | Sialyl Lewis expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer. 2018 , 15, 221-228 | 7 |
| 695 | Outcome of colon cancer initially presenting as colon perforation and obstruction. 2017 , 15, 164 | 31 |
| 694 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. 2017 , 23, 4675-4688 | 70 |
| 693 | Combined Detection of Preoperative Neutrophil-to-Lymphocyte Ratio and CEA as an Independent Prognostic Factor in Nonmetastatic Patients Undergoing Colorectal Cancer Resection Is Superior to NLR or CEA Alone. 2017 , 2017, 3809464 | 11 |
| 692 | Atypical presentation of sigmoid carcinoma. 2017 , 2017, rjx102 | |

| | | |
|-----|---|----|
| 691 | A review of preoperative chemoradiotherapy for lower rectal cancer. 2017 , 1, 65-73 | 3 |
| 690 | EMX2 gene expression predicts liver metastasis and survival in colorectal cancer. 2017 , 17, 555 | 15 |
| 689 | Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis. 2017 , 12, 156 | 8 |
| 688 | Lateral lymph node metastasis in a patient with T1 upper rectal cancer treated by lateral lymph node dissection: a case report and brief literature review. 2017 , 3, 93 | 3 |
| 687 | Significance of the E3 ubiquitin protein UBR5 as an oncogene and a prognostic biomarker in colorectal cancer. 2017 , 8, 108079-108092 | 7 |
| 686 | Lymph node evaluation for colon cancer in routine clinical practice: a population-based study. 2017 , 24, e35-e43 | 6 |
| 685 | UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. 2017 , 10, 61-68 | 31 |
| 684 | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. 2017 , 8, 4057-4064 | 10 |
| 683 | Age-adjusted charlson comorbidity index score as predictor of prolonged postoperative ileus in patients with colorectal cancer who underwent surgical resection. 2017 , 8, 20794-20801 | 24 |
| 682 | Patient considerations in metastatic colorectal cancer - role of panitumumab. 2017 , 10, 2033-2044 | 7 |
| 681 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. 2017 , 24, e261-e268 | 7 |
| 680 | Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. 2017 , 8, 77928-77941 | 8 |
| 679 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. 2017 , 8, 199-212 | 18 |
| 678 | Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients \geq 5 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. 2018 , 17, 307-312 | 15 |
| 677 | Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. 2018 , 423, 1-8 | 25 |
| 676 | Development and Validation of a Prediction Model for Postoperative Peritoneal Metastasis After Curative Resection of Colon Cancer. 2018 , 25, 1366-1373 | 8 |
| 675 | Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer. 2018 , 214, 402-407 | 21 |
| 674 | Late assessment of quality of life in patients with rectal carcinoma: comparison between sphincter preservation and definitive colostomy. 2018 , 33, 1039-1045 | 8 |

673 What Is the Ongoing Recommendation in the Management of Rectal Cancer?. **2018**, 59-67

672 What Chemotherapy to Recommend in Metastatic Patients?. **2018**, 339-348

671 What Are the Surgical Options in Patients with Synchronous Rectal Cancer?. **2018**, 449-454

670 How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery?. **2018**, 463-474

669 Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement. **2018**, 44, 1226-1232 6

668 Clinical Significance of Lymph Node Metastasis in the Mesentery of the Terminal Ileum in Patients With Right-sided Colon Tumors at Different Locations. **2018**, 61, 692-697 4

667 Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. **2018**, 41, 1189-1204 91

666 Transanal endoscopic surgery is effective and safe after endoscopic polypectomy of potentially malignant rectal polyps with questionable margins. **2018**, 20, 789-796 12

665 Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers. **2018**, 42, 705-714 43

664 What Are the Present Recommendations for Short-Course Preoperative Radiotherapy (RT) and Delayed Surgery?. **2018**, 229-235

663 Comparison of Western and Asian Guidelines Concerning the Management of Colon Cancer. **2018**, 61, 250-259 23

662 Comparisons of Rigid Proctoscopy, Flexible Colonoscopy, and Digital Rectal Examination for Determining the Localization of Rectal Cancers. **2018**, 61, 202-206 9

661 Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe. **2018**, 2, 6-12 31

660 Management of complex polyps of the colon and rectum. **2018**, 33, 115-129 13

659 Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis. **2018**, 8, 510 1

658 Disentangling the prognostic heterogeneity of stage III colorectal cancer through histologic stromal categorization. **2018**, 163, 777-783 16

657 S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. *Annals of Oncology*, **2018**, 29, 624-631 10.3 49

656 Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer. **2018**, 33, 1139-1142 6

| | | |
|-----|---|-----|
| 655 | Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. 2018 , 18, 297 | 49 |
| 654 | Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. 2018 , 10, 35 | 27 |
| 653 | Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. 2018 , 78, 115-124 | 13 |
| 652 | The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors. 2018 , 33, 719-726 | 4 |
| 651 | Comparison of survival between right-sided and left-sided colon cancer in different situations. 2018 , 7, 1141-1150 | 18 |
| 650 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 2018 , 19, 562-578 | 93 |
| 649 | Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. 2018 , 23, 982-990 | 10 |
| 648 | Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases. 2018 , 17, e307-e313 | 5 |
| 647 | Lipid polymer hybrid carrier systems for cancer targeting: A review. 2018 , 67, 86-100 | 23 |
| 646 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. 2018 , 23, 1-34 | 503 |
| 645 | Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer. 2018 , 41, 643-648 | 3 |
| 644 | Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study. 2018 , 24, 501-506 | 7 |
| 643 | Postoperative serum Vascular Endothelial Growth Factor is an independent prognostic factor of disease free survival and overall survival in patients with non metastatic colon cancer. 2018 , 216, 255-259 | 5 |
| 642 | Revisiting Dukes' paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. 2018 , 20, 794-800 | 6 |
| 641 | Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. 2018 , 17, e129-e142 | 15 |
| 640 | Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes. 2018 , 36, 3058-3076 | 22 |
| 639 | Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model. 2018 , 117, 737-744 | 18 |
| 638 | Improving prognosis and reducing decision regret for pancreatic cancer treatment using artificial neural networks. 2018 , 106, 110-118 | 41 |

| | | |
|-----|--|----|
| 637 | Management of Lateral Pelvic Lymph Nodes. 2018 , 213-230 | 1 |
| 636 | Optimal Surveillance Protocols After Curative Resection in Patients With Stage IV Colorectal Cancer: A Multicenter Retrospective Study. 2018 , 61, 51-57 | 10 |
| 635 | Quantitative assessment of a prognostic or predictive biomarker panel. 2018 , 28, 264-281 | 3 |
| 634 | Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagofodipir (PledOx): a placebo-controlled randomised phase II study (PLIANT). 2018 , 57, 393-402 | 52 |
| 633 | Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study. 2018 , 142, 1480-1489 | 25 |
| 632 | Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. 2018 , 38, 220-230 | 7 |
| 631 | Biomarkers in colorectal cancer: Current clinical utility and future perspectives. 2018 , 6, 869-881 | 73 |
| 630 | Evaluation of appropriate follow-up after curative surgery for patients with colorectal cancer using time to recurrence and survival after recurrence: a retrospective multicenter study. 2018 , 9, 25474-25490 | 8 |
| 629 | Adjuvant treatment in older patients with rectal cancer: a population-based review. 2018 , 25, e499-e506 | 5 |
| 628 | Individualized prediction of perineural invasion in colorectal cancer: development and validation of a radiomics prediction model. 2018 , 30, 40-50 | 33 |
| 627 | Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study. 2018 , 18, 1050 | 8 |
| 626 | High serum Hsp70 level predicts poor survival in colorectal cancer: Results obtained in an independent validation cohort. 2018 , 23, 539-547 | 8 |
| 625 | Mutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers. 2018 , 8, 487 | 14 |
| 624 | Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. 2018 , 10, 145-158 | 20 |
| 623 | Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A16 or UGT1A128. 2018 , 10, 6217-6226 | 5 |
| 622 | Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series. 2018 , 12, 875 | 1 |
| 621 | Association of Genetic Variants of Small Non-Coding RNAs with Survival in Colorectal Cancer. 2018 , 15, 217-222 | 1 |
| 620 | Combination of carcinoembryonic antigen with the American Joint Committee on Cancer TNM staging system in rectal cancer: a real-world and large population-based study. 2018 , 11, 5827-5834 | 8 |

| | | |
|-----|---|----|
| 619 | CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1 α /VEGF-A pathway in colorectal cancer. 2018 , 9, 974 | 54 |
| 618 | Insurance status does not affect short-term outcomes after oncological colorectal surgery in Europe, but influences the use of minimally invasive techniques: a propensity score-matched analysis. 2018 , 403, 863-872 | 2 |
| 617 | Simultaneous curative resection of double colorectal carcinoma with synchronous bilobar liver metastases. 2018 , 10, 293-316 | 3 |
| 616 | KISS1/KISS1R in Cancer: Friend or Foe?. 2018 , 9, 437 | 14 |
| 615 | Opposite functions of GSN and OAS2 on colorectal cancer metastasis, mediating perineural and lymphovascular invasion, respectively. 2018 , 13, e0202856 | 16 |
| 614 | High-risk Stage II Colorectal Cancers Carry an Equivalent Risk of Peritoneal Recurrence to Stage III. 2018 , 32, 1235-1240 | 2 |
| 613 | Cisatracurium Retards Cell Migration and Invasion Upon Upregulation of p53 and Inhibits the Aggressiveness of Colorectal Cancer. 2018 , 9, 941 | 11 |
| 612 | Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. 2018 , 61, 1016-1025 | 64 |
| 611 | High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer. 2018 , 119, 213-219 | 27 |
| 610 | Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer. 2018 , 30, 269-275 | 9 |
| 609 | ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer. 2018 , 104, 172-180 | 16 |
| 608 | Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer. 2018 , 109, 1939-1948 | 10 |
| 607 | Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer. 2018 , 17, e557-e568 | 1 |
| 606 | Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. 2018 , 119, 164-169 | 12 |
| 605 | Recent Strategies and Paradigm Shift in Management of Hepatic Metastasis from Colorectal Cancer. 2018 , 9, 456-460 | 1 |
| 604 | Tumor Budding in Colorectal Carcinoma: Translating a Morphologic Score Into Clinically Meaningful Results. 2018 , 142, 952-957 | 36 |
| 603 | Colorectal Cancer. 2018 , 111-125 | 1 |
| 602 | Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. 2018 , 38, 22 | 15 |

| | | |
|-----|--|-----|
| 601 | Circumferential resection margin as a prognostic factor after rectal cancer surgery: A large population-based retrospective study. 2018 , 7, 3673-3681 | 12 |
| 600 | Advantage of (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. 2018 , 9, 28691-28701 | 18 |
| 599 | The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: A retrospective cohort study. 2018 , 13, e0200893 | 15 |
| 598 | Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol. 2018 , 18, 459 | 14 |
| 597 | Risk factors of recurrence in T1 colorectal cancers treated by endoscopic resection alone or surgical resection with lymph node dissection. 2018 , 33, 1029-1038 | 11 |
| 596 | Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study. 2018 , 20, O162-O172 | 3 |
| 595 | Pathologic Assessment and Specimen Quality of Surgery After CME. 2018 , 277-283 | |
| 594 | Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. 2018 , 44, 1858-1864 | 4 |
| 593 | Eyes absent homologue 2 predicts a favorable prognosis in colorectal cancer. 2018 , 11, 4661-4671 | 2 |
| 592 | An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. 2018 , 143, 2758-2766 | 115 |
| 591 | Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer. 2018 , 12, 518-529 | 74 |
| 590 | Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?. 2018 , 10, 1758835918787993 | 7 |
| 589 | Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer. 2018 , 144, 2127-2137 | 17 |
| 588 | R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management. 2018 , 22, 1752-1763 | 25 |
| 587 | Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery. 2018 , 7, 28-33 | 4 |
| 586 | The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. 2019 , 17, 455-462.e6 | 41 |
| 585 | Comparison Between Laparoscopic and Open Resection Following Neoadjuvant Chemoradiotherapy for Mid-Low Rectal Cancer Patients: A Meta-Analysis. 2019 , 29, 316-322 | 3 |
| 584 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. 2019 , 33, 151-162 | 10 |

| | | |
|-----|---|----|
| 583 | Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer. 2019 , 3, 95-105 | 15 |
| 582 | Clinical significance and biological function of WD repeat domain 54 as an oncogene in colorectal cancer. 2019 , 144, 1584-1595 | 6 |
| 581 | Serum enterolactone concentrations are low in colon but not in rectal cancer patients. 2019 , 9, 11209 | 1 |
| 580 | Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. 2019 , 9, 11542 | 13 |
| 579 | Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. 2019 , 11, 243-251 | 1 |
| 578 | Prognostic lncRNAs, miRNAs, and mRNAs Form a Competing Endogenous RNA Network in Colon Cancer. 2019 , 9, 712 | 22 |
| 577 | Comparative Oncologic Outcomes of Upper Third Rectal Cancers: A Meta-analysis. 2019 , 18, e361-e367 | 9 |
| 576 | High efficacy and patient satisfaction with a nurse-led colorectal cancer surveillance programme with 10-year follow-up. 2019 , 89, 1286-1290 | 4 |
| 575 | Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. 2019 , 121, 303-311 | 2 |
| 574 | MRI-Based Radiomics Predicts Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 2019 , 9, 552 | 34 |
| 573 | Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report. 2019 , 11, 189-191 | 2 |
| 572 | Intracorporeal lymph node mapping in colon cancer surgery. 2019 , 45, 2316-2318 | 3 |
| 571 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. 2019 , 79, 1375-1394 | 29 |
| 570 | Synchronous pathologic findings in patients with colorectal cancer and preoperative incomplete colonoscopy. 2019 , 34, 1407-1412 | 0 |
| 569 | Anti-tumor effects of the ethanolic extract of seeds in colorectal cancer. 2019 , 14, 43 | 1 |
| 568 | Accuracy of nodal staging is influenced by sidedness in colon cancer. 2019 , 10, 902-909 | 2 |
| 567 | Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation. 2019 , 10, 459-468 | 6 |
| 566 | Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. 2019 , 7, 301-311 | 6 |

| | | |
|-----|---|----|
| 565 | Long-term outcome after one-stage surgery without preoperative decompression for stage II/III malignant colorectal obstruction: a propensity score-matched analysis. 2019 , 34, 1933-1943 | |
| 564 | Prediction of Clinical Pathologic Prognostic Factors for Rectal Adenocarcinoma: Volumetric Texture Analysis Based on Apparent Diffusion Coefficient Maps. 2019 , 43, 331 | 8 |
| 563 | Is primary tumor location an independent prognostic factor in stage IV colon cancer?. 2019 , 3, 196-202 | |
| 562 | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy. 2019 , 18, 1388-1394 | 7 |
| 561 | Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis. 2019 , 34, 1661-1671 | 8 |
| 560 | Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. 2019 , 121, 659-665 | 36 |
| 559 | Preoperative inflammatory response as prognostic factor of patients with colon cancer. 2019 , 404, 731-741 | 3 |
| 558 | A novel prognostic prediction tool for postoperative recurrence in patients with stage II/III colon cancer. 2019 , 39, 52 | 1 |
| 557 | Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study. 2019 , 34, 629-639 | 1 |
| 556 | Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases. 2019 , 45, 347-352 | 3 |
| 555 | Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer. 2019 , 74, 1005-1013 | 7 |
| 554 | Expression of CUEDC2 in colorectal cancer with different invasion and migration abilities. 2019 , 47, 905-914 | 4 |
| 553 | Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma. 2019 , 17, 655-667 | 1 |
| 552 | Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. 2019 , 17, 199 | 11 |
| 551 | Follow-Up After Gastric Cancer Treatment. 2019 , 327-340 | |
| 550 | EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. 2019 , 17, 208 | 19 |
| 549 | Oct4 Gene Expression in Primary Colorectal Cancer Promotes Liver Metastasis. 2019 , 2019, 7896524 | 14 |
| 548 | Laparoscopic Ovarian Transposition in Rectal Cancer: More than Just Oncological Outcomes. 2019 , 10, 309-312 | 0 |

| | | |
|-----|---|----|
| 547 | MRI in medical practice and its future use in radiation oncology. Resume of XXV GOCO Congress (Montpellier) 2017. 2019 , 24, 355-362 | |
| 546 | YY1-Induced Upregulation of Long Noncoding RNA ARAP1-AS1 Promotes Cell Migration and Invasion in Colorectal Cancer Through the Wnt/ β -Catenin Signaling Pathway. 2019 , 34, 519-528 | 29 |
| 545 | Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. 2019 , 5, 1118-1123 | 85 |
| 544 | Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. 2019 , 68, 1011-1024 | 46 |
| 543 | Effects of oxaliplatin-containing adjuvant chemotherapy on short-term survival of patients with colon cancer in Dr. Sardjito Hospital, Yogyakarta, Indonesia. 2019 , 10, 226-234 | 1 |
| 542 | Evaluation of encapsulated microparticles of <i>Garcinia mangostana</i> L. extracts on marker SGOT, SGPT, BUN and creatinine serum of BALB/c mice. 2019 , | 0 |
| 541 | Postoperative Oncologic Management of Colorectal Cancer Emergencies. 2019 , 233-239 | |
| 540 | Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. 2019 , 136, 106-112 | 8 |
| 539 | Comment on: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry". 2019 , 14, 365-366 | 1 |
| 538 | Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. 2019 , 120, 987-995 | 6 |
| 537 | Highly Sensitive O-Glycan Profiling for Human Serum Proteins Reveals Gender-Dependent Changes in Colorectal Cancer Patients. 2019 , 91, 6180-6189 | 10 |
| 536 | Obstruction is associated with perineural invasion in T3/T4 colon cancer. 2019 , 21, 917-924 | 7 |
| 535 | Current concepts in imaging for local staging of advanced rectal cancer. 2019 , 74, 623-636 | 4 |
| 534 | Natural language processing of German clinical colorectal cancer notes for guideline-based treatment evaluation. 2019 , 127, 141-146 | 10 |
| 533 | Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. 2019 , 17, 3890-3898 | 5 |
| 532 | Experience of the implementation and outcomes of universal testing for Lynch syndrome in the United Kingdom. 2019 , 21, 760-766 | 3 |
| 531 | Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. 2019 , 42, 331-341 | 40 |
| 530 | Fucosylation in cancer biology and its clinical applications. 2019 , 162, 93-119 | 26 |

| | | |
|-----|---|----|
| 529 | Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis. 2019 , 96, 191-200 | 16 |
| 528 | Early colorectal cancer: diagnosis, treatment and survivorship care. 2019 , 136, 20-30 | 39 |
| 527 | Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. 2019 , 49, 339-346 | 2 |
| 526 | Diagnostic and management strategies for lateral pelvic lymph nodes in low rectal cancer-a review of the evidence. 2019 , 10, 1200-1206 | 5 |
| 525 | TRIM44 Promotes Colorectal Cancer Proliferation, Migration, and Invasion Through the Akt/mTOR Signaling Pathway. 2019 , 12, 10693-10701 | 13 |
| 524 | MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer. 2019 , 11, | 6 |
| 523 | Rectal cancer treatment by transanal total mesorectal excision: Results in 100 consecutive patients. 2019 , 97, 510-516 | 0 |
| 522 | A nomogram for preoperative prediction of lymphatic infiltration in colorectal cancer: A personalized approach to clinical decision making. 2019 , 98, e18498 | 2 |
| 521 | Development and Validation of a Prediction Model for Organ-Specific Recurrences After Curative Resection of Colon Cancer. 2019 , 62, 1043-1054 | 1 |
| 520 | CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma. 2019 , 43, 1473-1482 | 16 |
| 519 | Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial. 2019 , 19, 1185 | 1 |
| 518 | Prognostic Value of Poorly Differentiated Clusters in Liver Metastatic Lesions of Colorectal Carcinoma. 2019 , 43, 1341-1348 | 8 |
| 517 | Association of Polyps with Early-Onset Colorectal Cancer and Throughout Surveillance: Novel Clinical and Molecular Implications. 2019 , 11, | 5 |
| 516 | Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. 2019 , 71, 599-624 | 1 |
| 515 | Medicinal Plants in the Prevention and Treatment of Colon Cancer. 2019 , 2019, 2075614 | 28 |
| 514 | Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer. 2019 , 102, 284-290 | 6 |
| 513 | Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies. 2019 , 21, 512-518 | 6 |
| 512 | Prognostic Implication of Negative Lymph Node Count in ypN+ Rectal Cancer after Neoadjuvant Chemoradiotherapy and Construction of a Prediction Nomogram. 2019 , 23, 1006-1014 | 7 |

| | | |
|-----|--|----|
| 511 | Quality of life and fear of cancer recurrence in T1 colorectal cancer patients treated with endoscopic or surgical tumor resection. 2019 , 89, 533-544 | 15 |
| 510 | Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2. 2019 , 38, 3019-3032 | 32 |
| 509 | Adjuvant Chemotherapy. 2019 , 81-100 | |
| 508 | A systematic review comparing radiation toxicity after various endorectal techniques. 2019 , 18, 71-86.e5 | 6 |
| 507 | Do the Oncological and Surgical Outcomes of Young and Older Women Differ in the Treatment of Colorectal Cancer?. 2019 , 28, 258-267 | |
| 506 | Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. 2019 , 8, e1537693 | 30 |
| 505 | Systematic review analysis of robotic and transanal approaches in TME surgery- A systematic review of the current literature in regard to challenges in rectal cancer surgery. 2019 , 45, 498-509 | 14 |
| 504 | Biliary duct stenosis after image-guided high-dose-rate interstitial brachytherapy of central and hilar liver tumors : A systematic analysis of 102 cases. 2019 , 195, 265-273 | 7 |
| 503 | Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial. 2019 , 24, 403-410 | 9 |
| 502 | Improved survival in rectal cancer patients who are treated with long-course versus short-course neoadjuvant radiotherapy: A propensity-matched analysis of the NCDB. 2019 , 119, 518-531 | 5 |
| 501 | Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. 2019 , 8, 133-142 | 6 |
| 500 | Symptoms during chemotherapy in colorectal cancer patients. 2019 , 27, 3007-3017 | 17 |
| 499 | Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review. 2019 , 50, 1029-1033 | |
| 498 | Thoracic recurrence in patients with curatively-resected colorectal cancer: incidence, risk factors, and value of chest CT as a postoperative surveillance tool. 2019 , 29, 4303-4314 | |
| 497 | The changing face of treatment for metastatic colorectal cancer. 2019 , 19, 61-70 | 8 |
| 496 | Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved. 2020 , 38, 107322 | 78 |
| 495 | DC-SIGN-LEF1/TCF1-miR-185 feedback loop promotes colorectal cancer invasion and metastasis. 2020 , 27, 379-395 | 15 |
| 494 | Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review. 2020 , 23, 114-126 | 4 |

| | | |
|-----|--|-----|
| 493 | Predicting lateral pelvic lymph node metastasis based on magnetic resonance imaging before and after neoadjuvant chemotherapy for patients with locally advanced lower rectal cancer. 2020 , 50, 292-297 | 3 |
| 492 | Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Stage I-II Rectal Cancer Patients. 2020 , 245, 281-287 | 7 |
| 491 | Racial Comparisons in Timeliness of Colon Cancer Treatment in an Equal-Access Health System. 2020 , 112, 410-417 | 9 |
| 490 | Biomarker-guided therapy for colorectal cancer: strength in complexity. 2020 , 17, 11-32 | 103 |
| 489 | Preoperative C-reactive protein-to-albumin ratio predicts anastomotic leak in elderly patients after curative colorectal surgery. 2020 , 27, 295-302 | 7 |
| 488 | Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. 2020 , 76, 433-446 | 11 |
| 487 | A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer. 2020 , 50, 352-359 | 3 |
| 486 | IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol. 2020 , 59, 336-341 | 10 |
| 485 | Population-based analysis of outcomes with early-age colorectal cancer. 2020 , 107, 301-309 | 15 |
| 484 | Lymph node retrieval after colorectal cancer surgery: a comparative study of the efficacy between the conventional manual method and a new fat dissolution method. 2020 , 50, 726-733 | 2 |
| 483 | Treatment of colon cancer with multiple liver metastases. 2020 , 33, 55-56 | |
| 482 | Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. 2020 , 27, 1036-1045 | 8 |
| 481 | Risk factors of short-term survival in the aged in elective colon cancer surgery: a population-based study. 2020 , 35, 307-315 | 9 |
| 480 | Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. 2020 , 20, 524-532 | 12 |
| 479 | METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing. 2020 , 28, 599-612 | 100 |
| 478 | KRT17 as a prognostic biomarker for stage II colorectal cancer. 2020 , 41, 591-599 | 9 |
| 477 | High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study. 2020 , 44, 101679 | 11 |
| 476 | Development of a novel prediction model for recurrent stage II colon cancer. 2020 , 50, 389-395 | 3 |

| | | |
|-----|--|----|
| 475 | Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. 2019 , 12, | 10 |
| 474 | Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer. 2020 , 13, 427-438 | 3 |
| 473 | Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis. 2020 , 10, 1681 | 3 |
| 472 | An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. 2020 , 1-27 | |
| 471 | Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study. 2020 , 10, 1682 | 3 |
| 470 | INHBB Is a Novel Prognostic Biomarker Associated with Cancer-Promoting Pathways in Colorectal Cancer. 2020 , 2020, 6909672 | 7 |
| 469 | Current Surgical Strategies for the Treatment of Rectal Adenocarcinoma and the Risk of Local Recurrence. 2021 , 39, 325-333 | |
| 468 | Colorectal Cancer Immunotherapy: Options and Strategies. 2020 , 11, 1624 | 52 |
| 467 | Prognostic impact of tumor budding and EMT in periampullary adenocarcinoma: a quantitative approach. 2020 , 11, 6474-6483 | 2 |
| 466 | Lateral pelvic lymph node dissection in the management of locally advanced low rectal cancer: Summary of the current evidence. 2020 , 35, 418-425 | 0 |
| 465 | Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. 2020 , 6, e202701 | 10 |
| 464 | Is It Time to Introduce PET/CT in Rectal Cancer Guidelines?. 2020 , 45, 611-617 | 4 |
| 463 | Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis. 2020 , 22, 1231-1244 | 13 |
| 462 | Research on Recognition of Medical Image Detection Based on Neural Network. 2020 , 8, 94947-94955 | 4 |
| 461 | Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer. 2020 , 19, e157-e163 | 1 |
| 460 | A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. 2020 , 147, 3250-3261 | 4 |
| 459 | Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?. 2020 , 12, | 8 |
| 458 | Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. 2020 , 5, e001040 | 0 |

| | | |
|-----|---|----|
| 457 | Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. 2020 , 5, e001001 | 3 |
| 456 | Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. 2020 , 10, 1115 | 14 |
| 455 | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. 2020 , 9, | 25 |
| 454 | Eosinophilic peritonitis with colon cancer: a case report. 2020 , 20, 353 | 1 |
| 453 | Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. 2021 , 20, 101-112.e6 | 1 |
| 452 | A Convolutional Neural Network based system for Colorectal cancer segmentation on MRI images. 2020 , 2020, 1675-1678 | 4 |
| 451 | Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. 2020 , 12, | 4 |
| 450 | The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. 2021 , 52, 932-939 | |
| 449 | Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. 2020 , 11, 1678 | 20 |
| 448 | Predictive and Prognostic Markers for Cancer Medicine. 2020 , 157-201 | 1 |
| 447 | A new fat-dissociation method to detect lymph nodes in colorectal cancer: a prospective randomized study. 2020 , 10, 20205 | 0 |
| 446 | Applicability of minimally invasive surgery for clinically T4 colorectal cancer. 2020 , 10, 20347 | 0 |
| 445 | Small Molecules for Multi-Wavelength Near-Infrared Fluorescent Mapping of Regional and Sentinel Lymph Nodes in Colorectal Cancer Staging. 2020 , 10, 586112 | 0 |
| 444 | Smoking status before and after colorectal cancer diagnosis and mortality in Korean men: A population-based cohort study. 2020 , 9, 9641-9648 | 1 |
| 443 | Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. 2020 , 12, | 10 |
| 442 | Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam. 2020 , 27, 1073274820968883 | 2 |
| 441 | The Clinical Significance of Lymphovascular Invasion in Gastric Cancer. 2020 , 34, 1533-1539 | 4 |
| 440 | Improved quality of colon cancer surveillance after implementation of a personalized surveillance schedule. 2020 , 122, 529-537 | 2 |

| | | |
|-----|--|----|
| 439 | Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. 2020 , 22, 1976-1991 | 7 |
| 438 | The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. 2020 , 127, 110232 | 9 |
| 437 | Total mesorectal excision with and without lateral lymph node dissection: a systematic review of the literature. 2020 , 35, 1183-1192 | 4 |
| 436 | Advances in Hereditary Colorectal Cancer: Opportunities and Challenges for Clinical Translation. 2020 , 8, 47-60 | |
| 435 | Prognosis of Patients with Colorectal Cancer with Diabetes According to Medication Adherence: A Population-Based Cohort Study. 2020 , 29, 1120-1127 | 2 |
| 434 | Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. 2020 , 12, | 2 |
| 433 | Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study. 2020 , 4, 685-692 | 14 |
| 432 | Weighted gene co-expression network analysis identified MYL9 and CNN1 are associated with recurrence in colorectal cancer. 2020 , 11, 2348-2359 | 7 |
| 431 | Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles. 2020 , 9, 3043-3056 | 3 |
| 430 | Recellularized Colorectal Cancer Patient-derived Scaffolds as in vitro Pre-clinical 3D Model for Drug Screening. 2020 , 12, | 17 |
| 429 | Prognosis of colorectal cancer patients is associated with the novel log odds of positive lymph nodes scheme: derivation and external validation. 2020 , 11, 1702-1711 | 6 |
| 428 | Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers. 2020 , 21, | 5 |
| 427 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. 2020 , 25, 1285-1290 | |
| 426 | Treatment approach in locally advanced rectal cancer during coronavirus (COVID-19) pandemic: long course or short course?. 2020 , 22, 642-643 | 18 |
| 425 | Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. 2020 , 121, 1320-1328 | 5 |
| 424 | Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer. 2020 , 13, 324-328 | 0 |
| 423 | Tumour budding and its clinical implications in gastrointestinal cancers. 2020 , 123, 700-708 | 6 |
| 422 | Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer. 2020 , 123, 973-981 | 6 |

| | | |
|-----|---|----|
| 421 | Is It Time to Introduce PET/CT in Colon Cancer Guidelines?. 2020 , 45, 525-530 | 3 |
| 420 | Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments. 2020 , 28, 2523-2532 | 20 |
| 419 | Nutritional risk screening score is associated with omission of adjuvant chemotherapy for stage III colon cancer. 2020 , 220, 993-998 | 0 |
| 418 | RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer. 2020 , 216, 152898 | 4 |
| 417 | Challenges of improving treatment outcomes for colorectal and anal cancers in Japan: the Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG). 2020 , 50, 368-378 | 3 |
| 416 | Detection of Nonpalpable Tiny Axillary Lymph Nodes Surrounded by Adipose Tissue Using a Near-Infrared Camera. 2020 , 18, 455-463 | 1 |
| 415 | Comparison of a Five-Year Survival and Cancer Recurrence between Laparoscopically Assisted and Open Colonic Resections due to Adenocarcinoma-a Single Centre Experience. 2020 , 56, | 0 |
| 414 | Treatment patterns for metastatic colorectal cancer in Spain. 2020 , 22, 1455-1462 | 3 |
| 413 | Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. 2020 , 72, 1-19 | 1 |
| 412 | The long noncoding RNA TUG1 is required for TGF- β /TWIST1/EMT-mediated metastasis in colorectal cancer cells. 2020 , 11, 65 | 35 |
| 411 | Comparison of sequential, delayed and simultaneous resection strategies for synchronous colorectal liver metastases. 2020 , 20, 16 | 4 |
| 410 | Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients. 2020 , 21, 1 | 11 |
| 409 | Transanal total mesorectal excision and adverse conditions for laparoscopic total mesorectal excision. 2020 , 52, 88-95 | 1 |
| 408 | Sarcopenia as a Risk Factor of Morbimortality in Colorectal Cancer Surgery. 2020 , 2, 107-117 | 1 |
| 407 | Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer. 2020 , 2020, 5419634 | 0 |
| 406 | Perioperative Therapie des CRC. 2020 , 23, 10-14 | |
| 405 | Prognostic value of a combination of innovative factors (gut microbiota, sarcopenia, obesity, metabolic syndrome) to predict surgical/oncologic outcomes following surgery for sporadic colorectal cancer: a prospective cohort study protocol (METABIOTE). 2020 , 10, e031472 | 5 |
| 404 | A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier. 2020 , 98, 534-541 | 5 |

| | | |
|-----|---|----|
| 403 | Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. 2020 , 16, 222-231 | 5 |
| 402 | Height of Rectal Cancer: A Comparison between Rectoscopic and Different MRI Measurements. 2020 , 2020, 2130705 | 4 |
| 401 | An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. 2020 , 18, 144 | 5 |
| 400 | Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). 2021 , 70, 114-126 | 20 |
| 399 | Can medical imaging identify the histopathological growth patterns of liver metastases?. 2021 , 71, 33-41 | 9 |
| 398 | How to accurately measure the distance from the anal verge to rectal cancer on MRI: a prospective study using anal verge markers. 2021 , 46, 449-458 | 4 |
| 397 | Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. 2021 , 148, 1575-1585 | 7 |
| 396 | Precision functional sphincter-preserving surgery (PPS) for ultralow rectal cancer: a natural orifice specimen extraction (NOSE) surgery technique. 2021 , 35, 476-485 | 3 |
| 395 | Colonic endoscopic submucosal dissection using a novel robotic system (with video). 2021 , 93, 1172-1177 | 4 |
| 394 | Stage migration resulting from inadequate number of examined lymph nodes impacts prognosis in stage II colon cancer after radical surgery. 2021 , 36, 959-969 | 2 |
| 393 | Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer. 2021 , 73, 7-21 | 3 |
| 392 | Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. 2021 , 87, 31-41 | 0 |
| 391 | Proposal for a post-operative surveillance strategy for stage I colorectal cancer patients based on a novel recurrence risk stratification: a multicenter retrospective study. 2021 , 36, 67-74 | 1 |
| 390 | Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. 2021 , 17, 84-93 | 4 |
| 389 | Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO. 2016 , 7, 42183-42194 | 56 |
| 388 | Altered Expression of MBNL Family of Alternative Splicing Factors in Colorectal Cancer. 2021 , 18, 295-306 | |
| 387 | Improved oncologic outcomes with increase of laparoscopic surgery in modified complete mesocolic excision with D3 lymph node dissection for T3/4a colon cancer: results of 1191 consecutive patients during a 10-year period: a retrospective cohort study. 2021 , 26, 893-902 | 0 |
| 386 | Extended Total Mesorectal Excision (e-TME) for Locally Advanced Rectal Cancer. 2021 , 1 | |

| | | |
|-----|--|----|
| 385 | Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. 2021 , 11, 441 | 5 |
| 384 | Combining PT and CEA Levels With the TNM Stage System to Identify Postoperative Recurrence Patients With Stage I-III Colorectal Cancer. | |
| 383 | mA regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. 2021 , 11, 2201-2217 | 54 |
| 382 | A panel of tumor biomarkers to predict complete pathological response to neo-adjuvant treatment in Locally Advanced Rectal Cancer. 2021 , | 1 |
| 381 | Expression of Thomsen-Friedenreich Antigen in Colorectal Cancer and Association with Microsatellite Instability. 2021 , 22, | |
| 380 | Clinical Significance of Preoperative Inflammatory Markers in Prediction of Prognosis in Node-Negative Colon Cancer: Correlation between Neutrophil-to-Lymphocyte Ratio and Poorly Differentiated Clusters. 2021 , 9, | 3 |
| 379 | ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer. 2021 , 35, 191-201 | 2 |
| 378 | Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. 2021 , 27, 208-216 | 3 |
| 377 | Impact of Lymphovascular Invasion in Patients With Stage II Colorectal Cancer: A Propensity Score-matched Study. 2021 , 35, 525-531 | 1 |
| 376 | Kolon. 2021 , 209-270 | |
| 375 | A novel prognosis marker based on combined preoperative carcinoembryonic antigen and systemic inflammatory response for resectable gastric cancer. 2021 , 12, 927-935 | 4 |
| 374 | Colorectal Cancer. 2021 , 1963-1989 | |
| 373 | Joint Tumor Bud-MMP/TIMP Count at the Invasive Front Improves the Prognostic Evaluation of Invasive Breast Carcinoma. 2021 , 9, | |
| 372 | Recurrence hazard of rectal cancer compared with colon cancer by adjuvant chemotherapy status: a nationwide study in Japan. 2021 , 56, 371-381 | 2 |
| 371 | The clinical features, management, and survival of elderly patients with colorectal cancer. 2021 , 12, 89-99 | 1 |
| 370 | A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors.. 2021 , 10, 1119-1130 | 0 |
| 369 | Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection. 2021 , 21, 179 | 2 |
| 368 | Which Definition of Upper Rectal Cancer Is Optimal in Selecting Stage II or III Rectal Cancer Patients to Avoid Postoperative Adjuvant Radiation?. 2020 , 10, 625459 | 0 |

| | | |
|-----|---|----|
| 367 | The Protein Secretome Is Altered in Rectal Cancer Tissue Compared to Normal Rectal Tissue, and Alterations in the Secretome Induce Enhanced Innate Immune Responses. 2021 , 13, | 5 |
| 366 | Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs. 2021 , 20, 503-521 | 1 |
| 365 | Staging Paradox and Discrepancy in Adjuvant Chemotherapy in Patients with T4N0, T1-2N1, and T3N1 Colon Cancer. 2021 , 45, 1561-1568 | |
| 364 | Dendritic cells loaded with exosomes derived from cancer stem cell-enriched spheroids as a potential immunotherapeutic option. 2021 , 25, 3312-3326 | 8 |
| 363 | Establishment and clinical application value of an automatic diagnosis platform for rectal cancer T-staging based on a deep neural network. 2021 , 134, 821-828 | 5 |
| 362 | A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. 2021 , 10, 1535-1544 | 2 |
| 361 | Vacuolar Membrane ATPase Activity 21 Predicts a Favorable Outcome and Acts as a Suppressor in Colorectal Cancer. 2020 , 10, 605801 | 0 |
| 360 | Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre. 2021 , 10781552211002912 | |
| 359 | Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center. 2021 , 12, 487316 | 1 |
| 358 | Emerging Trends for Radio-Immunotherapy in Rectal Cancer. 2021 , 13, | 6 |
| 357 | Improving tumor budding reporting in colorectal cancer: a Delphi consensus study. 2021 , 479, 459-469 | 4 |
| 356 | 5-Fluorouracil Cardiotoxicity: Known But Unknown. 2021 , 3, 110-112 | 0 |
| 355 | Efficacy of Herbal Medicines Intervention for Colorectal Cancer Patients With Chemotherapy-Induced Gastrointestinal Toxicity - a Systematic Review and Meta-Analysis. 2021 , 11, 629132 | 2 |
| 354 | Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study. 2021 , 21, 306 | 2 |
| 353 | Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review. 2021 , 20, 52-71 | 19 |
| 352 | Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. 2021 , 10, | 0 |
| 351 | Preliminary Study on Predicting Pathological Staging and Immunohistochemical Markers of Rectal Cancer Based on ADC Histogram Analysis. 2021 , 28 Suppl 1, S184-S191 | 1 |
| 350 | Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. 2021 , 60, 842-849 | 4 |

| | | |
|-----|---|---|
| 349 | Factors influencing treatment burden in colorectal cancer patients undergoing curative surgery: A cross-sectional study. 2021 , 30, e13437 | 0 |
| 348 | Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. 2021 , 11, e044239 | 4 |
| 347 | Identification of a ferroptosis-related gene signature predictive model in colon cancer. 2021 , 19, 135 | 7 |
| 346 | Serum carcinoembryonic antigen pre-operative level in colorectal cancer: revisiting risk stratification. 2021 , 91, E367-E374 | 3 |
| 345 | The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer. 2021 , 13, 3271-3280 | 2 |
| 344 | The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer. 2021 , 124, 97-105 | 1 |
| 343 | Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer: A Population-Based Study. 2021 , 10, | 1 |
| 342 | Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. 2021 , 157, 70-77 | 2 |
| 341 | Role of thyroid hormone-integrin $\alpha 5$ -signal and therapeutic strategies in colorectal cancers. 2021 , 28, 24 | 4 |
| 340 | Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). 2021 , 13, | 0 |
| 339 | HNF1A regulates colorectal cancer progression and drug resistance as a downstream of POU5F1. 2021 , 11, 10363 | 4 |
| 338 | Disheveled-associated activator of morphogenesis 2 promotes invasion of colorectal cancer by activating PAK1 and promoting MMP7 expression. 2021 , 43, 923-935 | 2 |
| 337 | Rectal cancer at the peritoneal reflection. Preoperative MRI accuracy and histopathologic correlation. Prospective study. 2021 , | |
| 336 | Total neoadjuvant treatment in locally advanced rectal cancer. 2021 , 14, 101044 | 0 |
| 335 | Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. 2021 , 156, 710-720 | 2 |
| 334 | Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway. 2021 , 21, 757 | 2 |
| 333 | Men and Those With a History of Smoking Are Associated With the Development of Postoperative Ileus Following Elective Colorectal Cancer Resection at a Private Academic Hospital in Johannesburg, South Africa: A Retrospective Cohort Study. 2021 , 8, 667124 | 1 |
| 332 | Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. 2021 , 22, | 3 |

- 331 Perineural invasion and number of retrieved lymph nodes are prognostic factors for T2N0 colon cancer. **2021**, 406, 1979-1985
- 330 Quality of resection in emergency colon cancer surgery: a retrospective study. **2021**, 17, 107-111
- 329 Rektumkarzinom. **2021**, 43, 235-245
- 328 Prognostic Nomogram of Prognosis-Related Genes and Clinicopathological Characteristics to Predict the 5-Year Survival Rate of Colon Cancer Patients. **2021**, 8, 681721 7
- 327 Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study. **2021**, 28, 9073-9083 7
- 326 Treatment outcomes of patients with involved resection margin after rectal cancer surgery: A nationwide population-based cohort study in South Korea. **2021**, 0
- 325 Neutrophil Extracellular Traps in Colorectal Cancer Progression and Metastasis. **2021**, 22, 5
- 324 Adjuvant Therapies in Colon Cancer.
- 323 Stage II colon cancer staging using the number of retrieved lymph nodes may be superior to current TNM staging for prognosis stratification: the Japanese study group for postoperative follow-up of colorectal cancer. **2021**, 36, 2205-2214
- 322 Emerging applications of radiomics in rectal cancer: State of the art and future perspectives. **2021**, 27, 3802-3814 4
- 321 Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. **2021**, 149, 1713-1722 2
- 320 The survival after recurrence of colorectal cancer: a retrospective study focused on time to recurrence after curative resection. **2021**, 1 0
- 319 The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK. **2021**, 563, 1-7 2
- 318 Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. **2021**, 13, 9
- 317 The clinical relevance of indeterminate lung nodules in patients with locally recurrent rectal cancer. **2021**, 47, 1616-1622 0
- 316 The Medial Border of Laparoscopic D3 Lymphadenectomy for Right Colon Cancer: Results from an Exploratory Pilot Study. **2021**, 64, 1286-1296 1
- 315 Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer. **2021**, 28, 2914-2927
- 314 Predictive factors for distant recurrence of colorectal cancer in patients after curative resection for stage I-III colorectal cancer in Australia. **2021**, 1

| | | |
|-----|--|---|
| 313 | Predicting local tumour progression after ablation for colorectal liver metastases: CT-based radiomics of the ablation zone. 2021 , 141, 109773 | 2 |
| 312 | Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing. 2021 , 13, | 1 |
| 311 | Survival Impact of Chronic Obstructive Pulmonary Disease or Acute Exacerbation on Patients with Rectal Adenocarcinoma Undergoing Curative Resection: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. 2021 , 13, | 1 |
| 310 | Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial). 2021 , 36, 2637-2647 | 1 |
| 309 | LINC00882 plays a tumor-promoter role in colorectal cancer by targeting miR-3619-5p to up-regulate CTNNB1. 2021 , 53, 29-29 | |
| 308 | Correlation Between the Distance to Mesorectal Fascia and Prognosis of Ct3 Rectal Cancer: A Multicenter Study Results of China. 2021 , | 2 |
| 307 | Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer. 2021 , 14, 5017-5028 | 2 |
| 306 | The sigmoid take-off as a landmark to distinguish rectal from sigmoid tumours on MRI: Reproducibility, pitfalls and potential impact on treatment stratification. 2021 , | 5 |
| 305 | Stand der Dinge beim Rektumkarzinom. 2021 , 25, 48-59 | |
| 304 | Transcriptome-based identification of molecular markers related to the development and prognosis of Colon cancer. 2021 , 40, 1114-1124 | 0 |
| 303 | Role of salt-inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells. 2021 , 24, | |
| 302 | One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer. 2021 , 11, 695726 | 0 |
| 301 | Texture Analysis in the Assessment of Rectal Cancer: Comparison of T2WI and Diffusion-Weighted Imaging. 2021 , 2021, 9976440 | 0 |
| 300 | Thymidylate synthase locus LOH in combination with genotype has prognostic and predictive significance in colorectal cancer. 2021 , 15, 235 | |
| 299 | Strawberry tree honey in combination with 5-fluorouracil enhances chemosensitivity in human colon adenocarcinoma cells. 2021 , 156, 112484 | 6 |
| 298 | Plasma MMP-1 Expression as a Prognostic Factor in Colon Cancer. 2021 , 266, 254-260 | 2 |
| 297 | Prognostic implications of chemotherapy-induced neutropenia in stage III colorectal cancer. 2021 , 267, 391-396 | |
| 296 | In vitro and in vivo activity of series of cationic dinuclearPt(II) complexes. 2021 , 225, 111619 | |

- 295 Stromal scoring in advanced colon and rectal cancer: Stroma-rich tumors and their association with aggressive phenotypes. **2022**, 28, 1-6
- 294 Digestive Tract Disease. **2021**, 511-552
- 293 Lung Brachytherapy: Experience from Germany. **2021**, 135-152
- 292 Identification of Potential Diagnostic and Prognostic Biomarkers for Colorectal Cancer Based on GEO and TCGA Databases. **2020**, 11, 602922 3
- 291 [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology]. **2021**, 54, 41-54
- 290 Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. **2021**, 118, 19
- 289 Recurrence risk factors in elderly patients with stage II colorectal cancer. **2021**, 29, 5-10
- 288 Colon and rectum. 308-326 1
- 287 Neue Arzneimittel 2013. **2014**, 47-145 2
- 286 Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan. **2018**, 41, 203-209 4
- 285 SNHG11 promotes cell proliferation in colorectal cancer by forming a positive regulatory loop with c-Myc. **2020**, 527, 985-992 9
- 284 Rectal cancer treatment by transanal total mesorectal excision: Results in 100 consecutive patients. **2019**, 97, 510-516 2
- 283 Evaluation of Recurrence Risk After Curative Resection for Patients With Stage I to III Colorectal Cancer Using the Hazard Function: Retrospective Analysis of a Single-institution Large Cohort. **2020**, , 3
- 282 Intramural metastasis to the appendix from ascending colon cancer: a case report. **2020**, 6, 69 1
- 281 Predictive Role of Functional Visceral Fat Activity Assessed by Preoperative F-18 FDG PET/CT for Regional Lymph Node or Distant Metastasis in Patients with Colorectal Cancer. **2016**, 11, e0148776 23
- 280 The Preoperative Peripheral Blood Monocyte Count Is Associated with Liver Metastasis and Overall Survival in Colorectal Cancer Patients. **2016**, 11, e0157486 16
- 279 A Nomogram to Predict Adequate Lymph Node Recovery before Resection of Colorectal Cancer. **2016**, 11, e0168156 3
- 278 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line. **2017**, 118, 128-138 1

| | | |
|-----|--|----|
| 277 | Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. 2016 , 50, 226-31 | 3 |
| 276 | [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases]. 2013 , 66, 325-30 | 2 |
| 275 | The relationship between tumor budding and survival in colorectal carcinomas. 2019 , 65, 1442-1447 | 2 |
| 274 | Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. 2016 , 7, 66160-66169 | 4 |
| 273 | Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma. 2016 , 7, 78688-78697 | 9 |
| 272 | Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. 2017 , 8, 37875-37883 | 11 |
| 271 | High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. 2017 , 8, 6970-6983 | 27 |
| 270 | Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer. 2017 , 8, 54604-54615 | 34 |
| 269 | Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis. 2017 , 8, 47356-47364 | 1 |
| 268 | Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance. 2017 , 8, 72494-72512 | 18 |
| 267 | Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. 2017 , 8, 103952-103967 | 5 |
| 266 | Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/ β -catenin signaling. 2017 , 8, 115803-115816 | 21 |
| 265 | Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. 2018 , 9, 33702-33709 | 4 |
| 264 | Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. 2015 , 6, 6151-9 | 17 |
| 263 | Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. 2015 , 6, 12558-73 | 56 |
| 262 | Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. 2015 , 6, 34004-13 | 12 |
| 261 | Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy. 2016 , 7, 1014-28 | 40 |
| 260 | Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche. 2016 , 7, 798-813 | 32 |

| | | |
|-----|---|----|
| 259 | [Diagnostic value of F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma]. 2019 , 51, 1071-1077 | 1 |
| 258 | Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). 2016 , 29, 103-26 | 12 |
| 257 | Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). 2016 , 29, 390-416 | 7 |
| 256 | Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases. 2017 , 31, 419-423 | 4 |
| 255 | Significance of gene polymorphism in development of colorectal cancer. 2020 , 28, 127-134 | 2 |
| 254 | Molecular biomarkers and histological parameters impact on survival and response to first-line systemic therapy of metastatic colorectal cancer patients. 2019 , 53, 85-95 | 5 |
| 253 | The Tendency of Having MSH2 and MSH6 Microsatellite Instability among Clinicopathological Features in Patients with Colorectal Cancer. 2018 , 19, 3147-3152 | 2 |
| 252 | Inhibition of Colorectal Cancer Cell Proliferation by Regulating Platelet-Derived Growth Factor B Signaling with a DNA Aptamer. 2019 , 20, 487-494 | 7 |
| 251 | 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. 2019 , 23, 1-88 | 13 |
| 250 | Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. 2013 , 19, 8474-88 | 8 |
| 249 | Prognostic and predictive significance of MSI in stages II/III colon cancer. 2014 , 20, 6809-14 | 57 |
| 248 | How to select the optimal treatment for first line metastatic colorectal cancer. 2014 , 20, 899-907 | 24 |
| 247 | Locally advanced rectal cancer: the importance of a multidisciplinary approach. 2014 , 20, 17279-87 | 21 |
| 246 | Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. 2016 , 22, 5332-41 | 16 |
| 245 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. 2016 , 22, 6345-61 | 69 |
| 244 | Novel predictors for lymph node metastasis in submucosal invasive colorectal carcinoma. 2017 , 23, 5936-5944 | 17 |
| 243 | Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. 2019 , 25, 4383-4404 | 75 |
| 242 | Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients. 2020 , 26, 4639-4655 | 9 |

| | | |
|-----|---|----|
| 241 | The location of locoregional recurrence in pathologic T3N0, non-irradiated lower rectal cancer. 2013 , 31, 97-103 | 7 |
| 240 | Identification of the Risk Factors for Recurrence of Stage II Rectal Cancer. 2014 , 67, 305-309 | 1 |
| 239 | Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study. 2020 , 12, 126-133 | 2 |
| 238 | Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer. 2020 , 19, 3567-3577 | 5 |
| 237 | The long non-coding RNA SNHG3 functions as a competing endogenous RNA to promote malignant development of colorectal cancer. 2017 , 38, 1402-1410 | 74 |
| 236 | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. 2019 , 34, 165-177 | 12 |
| 235 | Integrating anti-EGFR therapies in metastatic colorectal cancer. 2013 , 4, 285-98 | 17 |
| 234 | Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. 2018 , 7, 28 | 29 |
| 233 | Colorectal cancer screening guidelines for Nigeria in 2019. 2019 , 11, 42 | 2 |
| 232 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. 2016 , 48, 208-15 | 9 |
| 231 | Management of potentially resectable colorectal cancer liver metastases. 2013 , 5, 138-45 | 13 |
| 230 | Fat clearance and conventional fixation identified ypN0 rectal cancers following intermediate neoadjuvant radiotherapy have similar long-term outcomes. 2019 , 11, 877-886 | 1 |
| 229 | Prognostic and pathological impact of tumor budding in gastric cancer: A systematic review and meta-analysis. 2019 , 11, 898-908 | 7 |
| 228 | Precision medicine for gastrointestinal cancer: Recent progress and future perspective. 2020 , 12, 1-20 | 13 |
| 227 | Role of circulating free DNA in colorectal cancer. 2016 , 8, 810-818 | 5 |
| 226 | Adjuvant chemotherapy for rectal cancer: Is it needed?. 2015 , 6, 225-36 | 12 |
| 225 | Przerzuty do otrzewnej raka jelita grubego. 2017 , 89, 34-42 | 1 |
| 224 | Clinical Feasibility Assessment of T3 Sub-Stage in Rectal Cancer Using MRI. 2018 , 15, | 2 |

| | | |
|-----|---|----|
| 223 | Outcomes of local excision for early rectal cancer: a 6-year experience from the largest university hospital in Thailand. 2013 , 14, 5141-4 | 2 |
| 222 | Impact of an enhanced recovery program on colorectal cancer surgery. 2014 , 15, 3825-8 | 17 |
| 221 | Metastatic Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia Over Three Decades. 2015 , 16, 5923-31 | 5 |
| 220 | A logistic model including risk factors for lymph node metastasis can improve the accuracy of magnetic resonance imaging diagnosis of rectal cancer. 2015 , 16, 707-12 | 5 |
| 219 | Colorectal cancer treatment and survival: the experience of major public hospitals in south Australia over three decades. 2015 , 16, 2431-40 | 28 |
| 218 | New Prognostic Scoring System for Incurable Stage IV Colorectal Cancer. 2016 , 17, 597-601 | 7 |
| 217 | Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. 2020 , 12, e7305 | 2 |
| 216 | [Assessment of the metastatic potential of localized forms of colorectal cancer]. 2021 , 83, 5-12 | |
| 215 | Effect of Exercise Training on Quality of Life after Colorectal and Lung Cancer Surgery: A Meta-Analysis. 2021 , 13, | 3 |
| 214 | Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients. 2021 , 57, | 1 |
| 213 | Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis. 2021 , 1 | |
| 212 | Colorectal cancer liver metastases: An update of treatment strategy and future perspectives. 2021 , 7, 100042 | |
| 211 | High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. 2021 , 11, 755113 | 1 |
| 210 | Carcinomas of the Rectum and Anus. 2013 , 49-65 | |
| 209 | Oncologia. 2013 , 137-144 | |
| 208 | Challenges in the neoadjuvant treatment of rectal cancer. 2013 , 32-46 | |
| 207 | Imaging of Tumour Metabolism: 18-FDG PET. 2014 , 181-211 | |
| 206 | Bevacizumab maintenance in metastatic colorectal cancer: How long?. 2014 , 2, 717-23 | |

205 Rectal Cancer. **2015**, 411-448

204 Recurrence of liver metastases from colorectal cancer and repeat liver resection. **2015**, 107, 732-9

1

203 Value of Dual Assessment of Carcinoembryonic Antigen and Fluorine-18-Fluoro-Deoxyglucose Positron Emission Tomography in Colorectal Cancer Recurrence. **2015**, 5, 25-30

202 European Colorectal Cancer Management: Implemented as it is or Adapted to our National Specificity. **2015**, 61, 71-74

201 A Case of Obstructive Rectal Cancer Induced by a Japanese Apricot Seed. **2016**, 41, 89-93

200 The Analysis of Prognosis by Data Mining Using the Decision Tree Analysis in Stage III Colon and Rectosigmoid Cancer. **2016**, 41, 1-7

199 Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. **2016**, 168, 393-479

198 Hepatisch metastasiertes kolorektales Karzinom. **2016**, 67-77

197 RESULTS OF OPERATIONS IN COLON SURGERY WITH USAGE OF LAPAROSCOPIC TECHNIQUE AND ROBOTIC ASSISTANCE. **2016**, 40-47

1

196 Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. **2016**, 7, 46536-46544

1

195 PET/CT in Colorectal Cancer. **2017**, 49-55

194 Patient's Guide in Colorectal Cancer: Observation After Treatment and Treatment of Relapse. **2017**, 167-176

193 A Case of Lower Rectal Cancer with Submucosal Invasion that Had Lateral Lymph Node Metastases. **2017**, 78, 1050-1054

192 Colon and Rectum. 308-326

191 Chirurgische Therapieoptionen bei Lungenmetastasen. **2018**, 157-166


190 [Results of video-assisted technologies in colorectal surgery]. **2018**, 66-73

2

189 Kolon. **2018**, 181-225

188 Distribution of Lymph Nodes in Stage III Patients With Mid and Low Rectal Cancer: Preliminary Study. **2018**, 34, 42-46

1

- 187 Intensification thérapeutique dans la prise en charge du cancer colorectal métastatique : trichimiothérapie systémique et traitements intra-artériels hépatiques. **2018**, 12, 170-177
- 186 Long-term outcomes of neoadjuvant-synchronous S-1 plus radiotherapy for locally advanced rectal cancer: a multi-institutional prospective phase II study. **2018**, 2, 168-175 2
- 185 Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices. **2018**, 22-26 1
- 184 Correlation of the ganglionic and metastatic stages, before and after the surgery, of the cases of colon cancer diagnosed at the University hospital of Puerto real, period 2015-17. **2019**, 10,
- 183 The Swedish Approach. **2019**, 335-353 1
- 182 Emergencies Related to Primary Rectal Cancer. **2019**, 101-112
- 181  **2019**, 2, 29-32
- 180 Clinicopathological features and survival of colorectal cancer patients younger than 50 years: a retrospective comparative study. **2019**, 31, 6 1
- 179 Analysis of Treatment Option for Synchronous Liver Metastases and Colon Rectal Cancer. **2019**, 7, 4176-4178
- 178 The choice of local destruction method of colorectal cancer liver metastases. **2019**, 24, 30-36 2
- 177 Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients. **2019**, 35, 327-334 1
- 176 A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer. **2019**, 6, 67-69 1
- 175 Klinischer Stellenwert der Bildgebung nach neoadjuvanter Therapie. **2020**, 95-105
- 174 A Case of Late Recurrence of Colon Cancer After Curative Treatment. **2020**, 12, e8083
- 173 Comparing the initiation of adjuvant chemotherapy after robotic and laparoscopic colon cancer surgeries: A case-controlled study with propensity score matching. **2020**, 16, 9-17
- 172 Risk and treatment of non-hepatic cancers in patients with cirrhosis. **2020**, 28, 655-659
- 171 Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC). **2021**, 1 1
- 170 Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells. **2020**, 21, 1501-1508 4

- 169 Colorectal Cancer. **2020**, 1-27
- 168 Clonal architectures predict clinical outcome in colon adenocarcinoma. **2021**, 25, 1796-1800 1
- 167 A roadmap for medical treatment of metastatic CRC. **2022**, 365-379
- 166 Endoscopic ultrasound in CRC. **2022**, 89-94
- 165 Adjuvant chemotherapy for colorectal cancer. **2022**, 381-390
- 164 Comparison of Sequential, Delayed and Simultaneous Resection Strategies for Synchronous Colorectal Liver Metastases.
- 163 Präoperatives Staging des Rektumkarzinoms. **2020**, 71-78
- 162 Constructing early diagnosis model of colorectal cancer based on expression profile.
- 161 A Case of Rectal Submucosal Cancer with Negative Vascular Invasion and Lateral Lymph Node Metastases. **2020**, 81, 938-943
- 160 PET in Gastrointestinal, Pancreatic, and Liver Cancers. **2020**, 597-625
- 159 Comparison of Sequential, Delayed and Simultaneous Resection Strategies for Synchronous Colorectal Liver Metastases.
- 158 Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy. **2020**, 34, 3559-3564 1
- 157 Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC). **2020**, 11, 3-6 1
- 156 Endobronchial Metastasis of Colorectal Carcinoma. 2020,
- 155 Management of Colorectal Liver Metastases. **2021**, 553-574 0
- 154 Role of Imaging in Colorectal Cancers. **2021**, 123-151
- 153 Multidisciplinary Treatment of Rectal Cancer. **2021**, 163-178
- 152 Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. 0

| | | |
|-----|--|----|
| 151 | Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. 2016 , 29, 18-23 | 1 |
| 150 | Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. 2016 , 29, 3-17 | 16 |
| 149 | Overall Survival Associated With Ileostomy Closure in Patients With Rectal Cancer Before and After Adjuvant Therapy. 2017 , 17, 328-330 | 2 |
| 148 | Factors influencing the number of retrieved lymph nodes after colorectal resection: a retrospective study from a single institute. 2018 , 11, 1694-1700 | 1 |
| 147 | Circulating tumor DNA in colorectal cancer: opportunities and challenges. 2020 , 12, 1044-1055 | 12 |
| 146 | Computed tomography-based radiomics for predicting lymphovascular invasion in rectal cancer. 2021 , 146, 110065 | 1 |
| 145 | Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database. 2021 , | 0 |
| 144 | Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease. 2021 , 1 | 0 |
| 143 | Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance. 2021 , | 2 |
| 142 | Structured and shared MRI staging lexicon and report of rectal cancer: A consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer. 2021 , 103, 127-127 | 0 |
| 141 | Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study. 2021 , 33, 606-615 | 1 |
| 140 | Synchronous resection of primary colorectal cancer with liver metastases: two birds with one stone?. 2022 , | 2 |
| 139 | The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.. 2022 , 1 | |
| 138 | MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.. 2021 , 24, 76-85 | 0 |
| 137 | Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. 2021 , 146, 112488 | 2 |
| 136 | Maligne Dickdarntumoren. 2015 , 1-12 | |
| 135 | Quality of internet information to aid patient decision making in locally advanced and recurrent rectal cancer.. 2022 , | 0 |
| 134 | Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study.. 2022 , 11, | 0 |

| | | |
|-----|---|---|
| 133 | D3 Versus D2 Lymphadenectomy in Right Hemicolectomy: A Systematic Review and Meta-analysis.. 2022 , 15533506211060230 | 2 |
| 132 | Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients' Stratification.. 2021 , 11, 811486 | 0 |
| 131 | The Risk Analyses of Lymph Node Metastasis and Recurrence for Submucosal Invasive Colorectal Cancer: Novel Criteria to Skip Completion Surgery.. 2022 , 14, | 1 |
| 130 | Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.. 2022 , 1-8 | 0 |
| 129 | Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview.. 2022 , 22, 71 | 3 |
| 128 | YAP derived circ-LECRC functions as a "brake signal" to suppress hyperactivation of oncogenic YAP signalling in colorectal cancer.. 2022 , 532, 215589 | 0 |
| 127 | Clinical impact of postoperative prognostic nutritional index in colorectal cancer patients undergoing adjuvant chemotherapy. 2021 , 11, 4947-4955 | |
| 126 | Diagnostic Applications of Nuclear Medicine: Colorectal Cancer. 2022 , 1-14 | |
| 125 | Colorectal Cancer in Older Adults with Frailty. 2022 , 341-355 | |
| 124 | Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer.. 2022 , 12, 2990 | 0 |
| 123 | Distal Surgical Margin in Rectal Cancer. 1 | |
| 122 | -G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.. 2022 , 12, 826073 | 1 |
| 121 | Treatment pathways and associated costs of metastatic colorectal cancer in Greece.. 2022 , 20, 7 | 0 |
| 120 | Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).. 2022 , 22, 170 | |
| 119 | A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.. 2022 , 1 | 0 |
| 118 | An investigation on [5 fluorouracil and epigallocatechin-3-gallate] complex activity on HT-29 cell death and its stability in gastrointestinal fluid.. 2022 , 13, 476-489 | 0 |
| 117 | Assessment Following ESMO Recommendations for Colorectal Liver Metastases. Is It Always Worth It?. 2022 , 10, | 1 |
| 116 | Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.. 2022 , | 0 |

- 115 Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. **2022**, 32, 6-9
- 114 Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.. **2022**, 1
- 113 Local tuning of radiomics-based model for predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.. **2022**, 22, 44 0
- 112 Dual-Energy CT, Virtual Non-Calcium Bone Marrow Imaging of the Spine: An AI-Assisted, Volumetric Evaluation of a Reference Cohort with 500 CT Scans.. **2022**, 12,
- 111 Risk factors for the recurrence of stage II perforated colorectal cancer: A retrospective observational study.. **2022**,
- 110 Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage I-III colorectal cancer: a retrospective cohort study.. **2022**, 1 0
- 109 Percentage of Tumor Invasion at Pretreatment High-Resolution Magnetic Resonance Imaging: Associating With Aggressive and Tumor Response in Chinese T3 Rectal Cancer-Preliminary Results.. **2022**, 12, 616310
- 108 KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer.. **2022**, 22, 372 0
- 107 Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life: Practical lessons from a prospective cross-sectional, real-world study. **2022**, 10, 3101-3112 0
- 106 Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.. **2021**, 13, 25518-25549 0
- 105 Molecular Docking Analysis of Used Drugs for the Treatment of Cancer. 539-547
- 104 Development of a novel necroptosis-associated miRNA risk signature to evaluate the prognosis of colon cancer patients.. **2021**, 9, 1800 5
- 103 A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis.. **2022**, 84, 23 0
- 102 Laparoscopic Complete Mesocolic Excision with Central Vascular Ligation (CME + CVL) for Right-Sided Colon Cancer: A New "Superior Mesenteric Artery First" Approach.. **2022**,
- 101 Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography.. **2022**, 12,
- 100 Colorectal cancer and synchronous liver metastases: An individual case-based qualitative study (CoSMIC-Q).. **2022**, 1
- 99 Pelvic CT in addition to MRI to differentiate between rectal and sigmoid cancer on imaging using the sigmoid take-off as a landmark.. **2022**, 2841851221091209 1
- 98 Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study.. **2022**, 22, 390 0

97 Data_Sheet_1.docx. **2020**,

96 Image_1.png. **2020**,

95 Table_1.docx. **2020**,

94 Table_2.docx. **2020**,

93 Data_Sheet_1.docx. **2019**,

92 Presentation_1.pdf. **2020**,

91 DataSheet_1.docx. **2020**,

90 Video_1.mp4. **2020**,

89 Image_1.JPEG. **2018**,

88 Table_1.DOCX. **2018**,

87 Table_2.DOCX. **2018**,

86 Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location.. **2022**, 1

1

85 Tumors of the Small Intestine, Colon, and Rectum. **2022**, 223-244

84 Long Noncoding RNA MALAT1 and Colorectal Cancer: A Propensity Score Analysis of Two Prospective Cohorts.. **2022**, 12, 824767

83 Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.. **2022**, 13, 875764

0

82 Stage cT3 low rectal cancer: analysis of prognostic factors.. **2022**, 13, 672-682

81 Diagnostic Applications of Nuclear Medicine: Colorectal Cancer. **2022**, 1-14

80 Rectal cancer at the peritoneal reflection. Preoperative MRI accuracy and histopathologic correlation. Prospective study. **2022**,

| | | |
|----|--|---|
| 79 | A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. 2022 , 1-19 | |
| 78 | A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model. 2022 , 23, 6059 | 1 |
| 77 | Discovery and Validation of a Novel Metastasis-Related lncRNA Prognostic Signature for Colorectal Cancer. 2022 , 13, | 0 |
| 76 | Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. 2022 , 100342 | 0 |
| 75 | Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer. 2022 , 12, 1413 | 0 |
| 74 | Diagnostic accuracy of 6-slice spiral computed tomography for local staging of colon cancer: A systematic review and meta-analysis. 2022 , 10, 6483-6495 | |
| 73 | Survival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990-2016: The NORDCAN survival studies. 2022 , 172, 76-84 | 1 |
| 72 | An Overview of Essential Oil Anticancer Activity. 2022 , 391-413 | |
| 71 | Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. | 1 |
| 70 | Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. 12, | 0 |
| 69 | CLK2 Expression Is Associated with the Progression of Colorectal Cancer and Is a Prognostic Biomarker. 2022 , 2022, 1-11 | |
| 68 | Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. | 0 |
| 67 | Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice. 2022 , 18, 2701-2711 | |
| 66 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. 2015 , 44, 379-387 | 5 |
| 65 | m6A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer. 12, | 0 |
| 64 | Clinical efficacy of chemotherapy in colorectal cancer patients over 80 years old. | |
| 63 | E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. 2022 , 21, | 0 |
| 62 | Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery. 2022 , 110413 | 0 |

| | | |
|----|--|---|
| 61 | Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. | 0 |
| 60 | Assessment of mesorectal fascia status in MRI compared with circumferential resection margin after total mesorectal excision and predictors of involved margins. 2022, | |
| 59 | CT radiomics identifying non-responders to neoadjuvant chemoradiotherapy among patients with locally advanced rectal cancer. | 1 |
| 58 | m6A Regulator-Based Exosomal Gene Methylation Modification Patterns Identify Distinct Microenvironment Characterization and Predict Immunotherapeutic Responses in Colon Cancer. 2022, 2022, 1-25 | |
| 57 | A systematic review of selected plants and their metabolites with anticoloctal cancer effects. 2022, 2, 100332 | 0 |
| 56 | A Fokker-Planck framework for parameter estimation and sensitivity analysis in colon cancer. 2022, | 0 |
| 55 | Investigation of Automatic T-staging of Rectal Cancer Patients Based on 3D Convolutional Neural Networks. 2022, 259-265 | 0 |
| 54 | Diagnostic Applications of Nuclear Medicine: Colorectal Cancer. 2022, 919-932 | 0 |
| 53 | A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. 2022, 3877-3895 | 0 |
| 52 | The noncoding RNAs regulating pyroptosis in colon adenocarcinoma were derived from the construction of a ceRNA network and used to develop a prognostic model. 2022, 15, | 0 |
| 51 | Extramural vascular invasion as an independent prognostic marker in locally advanced rectal cancer: propensity score match pair analysis. | 0 |
| 50 | Biological Activity of Extracts from Differently Produced Blueberry Fruits in Inhibiting Proliferation and Inducing Apoptosis of HT-29 Cells. 2022, 11, 3011 | 0 |
| 49 | Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. 1-11 | 0 |
| 48 | Relationship between the timing of chemotherapy and surgical complications following surgical biopsy in children with malignant solid tumors. | 0 |
| 47 | Histopathological growth patterns determines the outcomes of colorectal cancer liver metastasis that have undergone liver resection. | 1 |
| 46 | Long-term oncologic outcomes of intersphincteric resection versus abdominoperineal resection for low rectal cancer without preoperative therapy. | 0 |
| 45 | Is There a Role for Adjuvant Chemotherapy in Pathologic Node-Negative Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy?. | 0 |
| 44 | Practical Implications of KRAS Mutation Status and Sidedness of Primary Tumour in Patients with Colorectal Cancer and Synchronous Liver Metastases: A Subset Analysis of the CoSMIC Study. 2022, 14, 4833 | 1 |

- 43 Systematic review of shared decision-making in guidelines about colorectal cancer screening. 0
- 42 CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule. **2022**, 22, 0
- 41 Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study. 9, 0
- 40 Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. **2022**, 15
- 39 Effect of lateral lymph nodes without malignant characteristics on the prognosis of patients with rectal cancer. 0
- 38 Dihydropyridinol inhibits the proliferation and growth of oxaliplatin-resistant human HCT116 colorectal cancer cells. **2022**, 27, 7774 0
- 37 A GNAS gene mutation-independent expression in the growth of colorectal cancer: A systematic review and meta-analysis. **2022**, 14, 5480 0
- 36 High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. 12, 1
- 35 Identification of necroptosis-related genes for predicting prognosis and exploring immune infiltration landscape in colon adenocarcinoma. 12, 0
- 34 Can CT pelvimetry be used to predict circumferential resection margin positivity in laparoscopic resection of middle and lower rectum cancer?. **2022**, 0
- 33 Are chemical compounds in medicinal mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?. **2022**, 22, 0
- 32 CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer. 0
- 31 Classification of rectal cancer according to recurrence types - comparison of Japanese guidelines and Western guidelines. 10, 13284-13292 0
- 30 Clinical feasibility of the therapeutic strategies total neoadjuvant therapy and "watch and wait" in the treatment of rectal cancer patients with recurrence after clinical complete response. 9, 0
- 29 A literature review in immuno-oncology: Pathophysiological and clinical features of colorectal cancer and the role of the doctor-patient interaction. **2022**, 13, 654-684 0
- 28 MXRA8 is an immune-related prognostic biomarker associated with metastasis and CD8+ T cell infiltration in colorectal cancer. 12, 0
- 27 SN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma. 0
- 26 Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: A population-based study. 0

- 25 Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment. **2023**, 15, 181 ○
- 24 The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer. **2023**, 13, 62 ○
- 23 CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer. **2023**, 15, 206 ○
- 22 Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. **2023**, 15, 258 ○
- 21 Predictors of treatment refusal in patients with colorectal cancer: A systematic review. **2023**, ○
- 20 Gastrocolic fistula caused by transverse colon cancer: a case report. **2023**, 9, ○
- 19 Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. **2023**, 137-144 ○
- 18 Artificial intelligence to investigate predictors and prognostic impact of time to surgery in colon cancer. **2023**, 127, 966-974 ○
- 17 The Management of Oligometastatic Disease in Colorectal Cancer: Present Strategies and Future Perspectives. **2023**, 103990 ○
- 16 A multicenter investigation of risk factors for recurrence in elderly patients with stage II colorectal cancer. **2023**, 31, 1-6 ○
- 15 Measuring distance from lowest boundary of rectal tumor to anal verge on CT images using pyramid attention pooling transformer. **2023**, 155, 106675 ○
- 14 Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?. **2023**, 318, 121504 2
- 13 Development of an immune-related gene prognostic risk model and identification of an immune infiltration signature in the tumor microenvironment of colon cancer. **2023**, 23, ○
- 12 The Potential Chemopreventive Effect of *Andrographis paniculata* on 1,2-Dimethylhydrazine and High-Fat-Diet-Induced Colorectal Cancer in Sprague Dawley Rats. **2023**, 24, 5224 ○
- 11 Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. **2023**, 15, 1679 ○
- 10 LncRNA CAC1nc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. **2023**, 42, 1374-1391 ○
- 9 Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma: a systematic review and meta-analysis. **2023**, 38, ○
- 8 Integrative analysis revealed that distinct cuproptosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer. 14, ○

- 7 The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) in real-life data report 2013-2018. **2023**, 57, 103-110
- 6 The effect of preoperative endoscopic tattooing using India ink on lymph node yield in laparoscopic colectomy for stage I right-sided colon cancer. **2023**, 38,
- 5 The effect of the HALP Score on survival in colorectal cancers. **2023**, 182,
- 4 Risk factors for postoperative recurrence of ulcerative colitis-associated colorectal cancer.
- 3 Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. 29, 1911-1941
- 2 Expression of anoikis-related genes and potential biomarkers in colon cancer.
- 1 Development and validation of a prognostic nomogram for rectal cancer patients who underwent surgical resection. 29,